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Investigating the association between Cannabis, the endogenous cannabinoid system and 
schizophrenia must take into account two aspects of major relevance. 
On the one hand, Cannabis is the most widely used illegal drug and there is substantial 
evidence that its consumption has to be classified as an independent risk factor for 
psychosis that may lead to a worse outcome of the disease. On the other hand, there are 
several lines of evidence that clearly indicate the presence of a dysregulation in the 
endocannabinoid system in animal models of psychosis and at least in a subgroup of 
schizophrenic patients. 
Concerning the first point, our recent studies in female rats demonstrated that chronic THC 
treatment during adolescence induced a complex phenotype in adulthood characterized by 
the presence of anhedonia, behavioral despair in the forced swim test, reduced sociability 
as well as significant deficits in spatial working and object recognition memory. Moreover, 
adolescent THC administration also sensitizes to the locomotor activating effect induced 
by acute psychostimulant administration in adulthood. This response is consistent with the 
presence of a psychotic-like phenotype. Thus, the simultaneous presence of pronounced 
depressive-like behaviors, cognitive deficits as well as psychotic-like signs suggests that 
adolescent THC exposure had led to a behavioral phenotype in adulthood that reflects the 
presence of complex schizoaffective-like disorder. Interestingly, when the same protocol of 
THC exposure was performed in adult animals, no behavioral alterations were observed, 
thus highlighting the specific vulnerability of the adolescent brain to the long-lasting 
adverse effects of THC. 
The neurobiology of cannabis-induced schizophrenia is still unknown. However, we 
recently demonstrated that adolescent exposure to THC produces-long lasting alterations 
in  the endocannabinoid system, that ultimately could result in imbalances of excitatory 
and inhibitory neurotransmission within specific brain regions. Accordingly, our data 
demonstrate that the schizoaffective-like disorder induced by adolescent THC exposure in 
female rats is strictly associated with alterations in the inhibitory neurotransmission which 
are particularly prominent within the prefrontal cortex, a brain region that has been found 
to be severely affected in schizophrenia. 
With regard to the second aspect, there are several lines of evidence that clearly indicate 
the presence of a dysregulation in the endocannabinoid system in different animal models 
of psychosis and based on these observations, the pharmacological modulation of the 
endocannabinoid system has been taken into account as a new therapeutic possibility for 
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psychotic disorders. In line with this, we demonstrated that chronic treatment with the 
cannabinoid CB1 receptor antagonist, AM251, counteracts the psychotic-like phenotype in 
a neurodevelopmental model of schizophrenia in rats. This recovery at behavioral level 
was paralleled by the normalization of the endocannabinoid system functionality both in 
terms of endocannabinoid levels and CB1 receptor/G protein coupling in all the brain areas 
analyzed, possibly suggesting that the ability of AM251 to restore normal endocannabinoid 
system may account for its antipsychotic action. 
As a whole, data reported in this thesis, strongly suggest an association between an 
altered endocannabinoid tone and the development of psychotic symptoms, thus 
supporting the exploitation of compounds acting on the endocannabinoid system as new 
therapeutic agents in the treatment of schizophrenia and related disorders. 
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1. The endocannabinoid system 
The term ‘endocannabinoid system’ refers to a neuromodulatory system present both in 
the brain and periphery comprising the cannabinoid CB1 and CB2 receptors, their intrinsic 
lipid ligands, endocannabinoids, such as the N-arachidonoylethanolamide (anandamide, 
AEA) and the 2-arachidonoylglycerol (2-AG), and the associated enzymatic machinery 
(transporters, biosynthetic and degradative enzymes). 
Two types of cannabinoid receptors have been characterized, named CB1 and CB2 based 
on the order of their discovery (Matsuda et al., 1990; Munro et al., 1993), both belonging to 
the superfamily of G protein coupled receptors, whose activation mediates most of the 
effects of cannabinoid drugs.  CB1 receptors are highly distributed in the CNS with low to 
moderate expression in periphery whereas CB2 receptors are predominately located in 
immune cells in tissues and recent papers demonstrate that they may also be expressed 
in neurons (Brusco et al., 2008; Gong et al., 2006; Van Sickle et al., 2005). The CB1 
receptor activation through both Gi/o proteins inhibits adenylyl cyclase activity, activates 
potassium channels and inhibits voltage-gated calcium channels, while the CB2 receptor is 
known only to couple to Gi proteins (Howlett, 2002). Some indirect evidence suggests the 
presence of additional cannabinoid receptors (GPR55, GPR119, PPAR) (Ryberg et al., 
2007; O’Sullivan, 2007) but to date only CB1 and CB2 receptors are recognized by The 
International Union of Basic and Clinical Pharmacology. 
Endogenous ligands for the cannabinoid receptors were discovered soon after their 
characterization. The two major known endogenous ligands are AEA and 2-AG (Devane et 
al., 1992; Stella et al., 1997; Sugiura et al., 2006). Both are arachidonic acid derivatives 
produced from phospholipid precursors postsynaptically through activity-dependent 
activation of specific phospholipase enzymes (Piomelli, 2003). Later on, a number of other 
endocannabinoid ligands have been identified including N- arachidonoyldopamine 
(NADA), N-arachidonoylglycerolether and O-arachidonoylethanolamine (De Petrocellis 
and Di Marzo, 2009). 
These ligands do not share the same biosynthetic or metabolic pathways, indicating 
distinct mechanisms of regulation. Different pathways can produce AEA from the 
phospholipid precursors N-arachidonoyl-phosphatidylethanolamine, the most relevant 
being a direct conversion catalysed by an N-acyl-phosphatidylethanolamine selective 
phosphodiesterase. 2-AG is mainly synthesized through activation of phospholipase C and 
the subsequent production of diacylglycerol, which is rapidly converted to 2-AG by 
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diacylglycerol lipase. After its re-uptake, AEA is hydrolysed by the enzyme fatty acid amide 
hydrolase (FAAH), producing arachidonic acid and ethanolamine, while 2-AG is primarily 
metabolized by monoacylglycerol lipase (MAG lipase), leading to the formation of 
arachidonic acid and glycerol (Di Marzo and Petrosino, 2007). Apart from their well known 
binding to CB1 and CB2 receptors, endocannabinoids may also bind to other receptors: for 
example AEA may activate intracellularly the potential vanilloid receptor type 1 (TRPV1) 
(Ross, 2003). Moreover, other putative cannabinoid receptors are the ‘orphan’ G protein 
coupled receptor, GPR55 (Ryberg et al., 2007), and the peroxisome proliferator activated 
receptor, PPAR (O’Sullivan, 2007). However, CB1 and CB2 receptors are certainly the 
most known targets for AEA and 2-AG, which activate them with different affinity: AEA has 
the highest affinity in both cases, whereas 2-AG has the highest efficacy in both cases 
(McPartland et al., 2007). 
Importantly, endocannabinoids are synthetized and released “on demand” by post synaptic 
cells through the cleavage of membrane phospholipid precursors in response to different 
physiological and pathological stimuli. Released endocannabinoids act as retrograde 
transmitters and traverse back across the synapse where they bind pre synaptically 
located CB1 receptors and reduce synaptic transmitter release (Freund et al., 2003). 
On this basis, the endocannabinoid system can be considered one of the major players in 
regulating the activity state of various neurotransmitters, and endocannabinoids are 
involved in several physiological functions and dysregulation of the endocannabinoid 
system has been associated with various pathological states, including psychiatric 
disorders. Recent data suggest that changes in endocannabinoid signaling and their 
consequences on neuronal activity might be important in the aetiology of schizophrenia 
and may explain the impact of cannabis abuse in psychotic disorders. 
2. Cannabis and schizophrenia 
The association between cannabis use and psychosis has long been recognized. Recent 
advances in knowledge about cannabinoid receptor function have renewed interest in this 
association. Converging lines of evidence suggest that cannabinoids can produce a full 
range of transient schizophrenia-like positive, negative, and cognitive symptoms in some 
healthy individuals. Also clear is that in individuals with an established psychotic disorder, 
cannabinoids can exacerbate symptoms, trigger relapse, and have negative 
consequences on the course of the illness. The mechanisms by which cannabinoids 
produce transient psychotic symptoms, while unclear may involve dopamine, GABA, and 
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glutamate neurotransmission. However, only a very small proportion of the general 
population exposed to cannabinoids develop a psychotic illness. It is likely that cannabis 
exposure is a “component cause” that interacts with other factors to “cause” schizophrenia 
or a psychotic disorder, but is still debated whether it could represent either a sufficient or 
necessary factor to do so alone. Nevertheless, in the absence of known causes of 
schizophrenia, the role of component causes remains important and warrants further 
study. Dose, duration of exposure, and the age of first exposure to cannabinoids may be 
important factors, and genetic factors that interact with cannabinoid exposure to moderate 
or amplify the risk of a psychotic disorder are beginning to be elucidated (D’Souza et al., 
2009). In particular, the risk to develop psychotic symptoms associated with cannabis 
consumption appears to be highly dependent upon the frequency of cannabis use (Di Forti 
et al, 2009) as well as the age when drug use begins, adolescence representing a more 
vulnerable time window for the long-term adverse effect of cannabis consumption (Malone 
et al, 2010; Rubino et al, 2012). 
2.1 The endocannabinoid system and schizophrenia 
Besides the “exogenous cannabinoid hypothesis” of schizophrenia referring to the risk 
factor associated with cannabis abuse  (see above), an “endogenous hypothesis” has 
been recently put forward referring to the presence of  dysregulations of the 
endocannabinoid system contributing to the pathophysiology of schizophrenia (Müller-Vahl 
and Emrich, 2008). Indeed, the distribution of cannabinoid receptors in brain areas 
implicated with schizophrenia such as prefrontal cortex (PFC), basal ganglia, hippocampus 
and anterior cingulated cortex (ACC) is consistent with a crucial role of the 
endocannabinoid system in this pathology. 
Based on these considerations, in the following sections the effect of chronic cannabis 
exposure in adolescence as a risk factor  for developing psychotic-like behavior later in life 
(exogenous stimulation) as well as the alterations of the endocannabinoid system present 
in schizophrenia and their possible role as target for new therapeutic approaches 
(endogenous hypothesis) will be reviewed, taking into account both experimental data and 
human studies. 
Before reviewing available data on the above-mentioned topics, a brief overview on animal 
models of schizophrenia will be provided. 
2.2 Methodological considerations on rodent models of schizophrenia 
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Animal models are important for studying psychiatric diseases as they allow the use of 
methods that for ethical reasons cannot be used in humans and enable the researcher to 
examine hypotheses regarding the development of these diseases in a controlled 
environment that would not be possible in human studies. It is, however, critical to note 
that due to the complex human psychopathology of psychiatric diseases, it is not possible 
to model a disease like schizophrenia in its entirety. In fact, it is impossible to model in 
rodents most symptoms observed in schizophrenic patients, such as delusions, 
hallucinations and disorganized thinking. Current approaches to the development of 
relevant animal models rely on focusing on specific signs or symptoms associated with 
schizophrenia, rather than mimicking the entire syndrome. Cognitive functioning is 
moderately to severely impaired in patients with schizophrenia. The profile of deficits in 
schizophrenia involves several domains of learning and memory. For example, recognition 
memory in both nonverbal and verbal modalities is impaired in schizophrenia (McGuire et 
al. 2013) and impairments in this domain of memory can be easily assessed in rodents 
through the novel object recognition test. Behavioral models of negative symptoms that 
are currently used in the development of novel antipsychotic agents include the social 
withdrawal model and the forced swim test. For instance, social withdrawal is often one of 
the earliest symptoms to occur in schizophrenia. The social interaction test allows to 
measures explorative and social behaviors between pairs of animals in a either familiar or 
unfamiliar environment. Finally, the assessment of the immobility in the FST represents a 
useful model for the negative symptoms of the disease, particularly the depressive 
features (Chindo et al. 2012). However, the cognitive deficits and the negative symptoms 
of schizophrenia have a partial overlap with other neurological disorders, therefore one 
limitations of the above mentioned tasks is that they are not specific for schizophrenia. In 
contrast, PPI response as well as increased sensitivity to the locomotor-activating effects 
of psychostimulants such as PCP are considered more specific to schizophrenia and this 
model is currently used to validate animal models of schizophrenia and to assess the 
efficacy of novel antipsychotic treatments. 
Despite the limitations, studies in experimental animals can provide potentially important 
new insight into a range of brain mechanisms with relevance to schizophrenia, such as 
detailed investigations on the role of certain brain areas in behavior, the mechanism of 
action of psychoactive and antipsychotic drugs, the interaction of classical and ‘novel’ 
neurotransmitters and genes in brain function, and neurodevelopmental mechanisms. 
Several of these studies would be very difficult to carry out in humans, both from a 
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technical and an ethical point of view. Clearly, complex psychiatric illnesses, such as 
schizophrenia, cannot be exactly reproduced in species such as rats and mice. 
Nevertheless, animal models are an important tool in studying the symptoms and 
development of such illnesses, alongside approaches such as post-mortem studies, 
psychophysiological studies, imaging and epidemiology. 
2.3 Effect of Adolescent exposure to cannabinoids and schizophrenia-like 
behaviour: animal studies 
Hyperlocomotion and sensorimotor gating 
Experimental studies dealing with long-lasting effects of adolescent cannabinoid exposure 
on psychosis-related behaviors in adult rodents are very scarce. 
Only two papers have addressed the effect of chronic pubertal cannabinoid exposure on 
sensorimotor gating at adulthood and report a long-lasting PPI deficit (Schneider and 
Koch, 2003; Wegener and Koch, 2009). 
The concept of testing for locomotor hyperactivity in animal models as a symptom of 
psychosis is based upon the premises that enhanced dopaminergic activity in rodents 
leads to enhanced motor activity (Geyer, 2008) and changes in dopaminergic activity, and 
although they are unlikely to be the primary cause of positive symptoms of schizophrenia, 
may be involved in varying degrees of symptomatology (Van den Buuse, 2010). Therefore 
locomotor hyperactivity, either at baseline or after treatment with psychoactive drugs, such 
as amphetamine or phencyclidine, has become widely used as a behavioral tool to 
investigate psychosis-like behaviors. 
As for PPI, few papers extensively investigated basal locomotor activity in adult animals 
pre-exposed to cannabinoids during adolescence and they reported confounding results: 
some of them showed no significant alterations in the open field recordings (Biscaia et al., 
2003; Rubino et al., 2008), while others stated the presence of locomotor hyperactivity 
(Wegener and Koch, 2009). 
So far, no published paper dealt with the consequence of cannabinoid adolescent 
exposure on psychoactive drug-induced locomotor activation. 
Cognitive deficits 
When recognition memory was tested through the novel object recognition test, most 
papers reported impairments after chronic cannabinoid treatment during adolescence that 
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were evident from 15 days to 30 days after discontinuing the treatment (O’Shea et al., 
2004, 2006; Quinn et al., 2008; Realini et al., 2010; Schneider and Koch, 2003). These 
impairments were present in both males and females, were induced by both the natural 
and synthetic cannabinoid compounds, and did not occur when the treatment was 
performed at adulthood. The only discrepant finding was by Higuera-Matas et al. (2009), 
who reported no significant effect of chronic CP55,940 during adolescence on recognition 
memory in both male and female adult rats. However, it is worth noting that they tested 
animals after a longer withdrawal period, i.e. 59 days, and maybe at this interval of time 
the long-lasting behavioral changes were recovered. If this is true, the effect of adolescent 
cannabis exposure on cognition might be considered as long-lasting and not irreversible, a 
feature really relevant at epidemiological level. Further studies are needed to make this 
point clearer. Spatial learning assessed through the Morris water maze was not affected 
by adolescent exposure to natural or synthetic cannabinoids in both male or female rats 
(Cha et al., 2006, 2007; Higuera-Matas et al., 2009). However, spatial working memory in 
the radial maze was impaired in both genders (Rubino et al., 2009a, 2009b). 
As a general conclusion, the cognitive deficit appears to be task-specific, thus suggesting 
impairments in specific components of learning and memory rather than widespread 
effects: in particular, it appears that whenever the working memory component is involved 
in the test performance, a deficit is observed. 
Social behaviors 
Characteristic features of negative symptoms of schizophrenia are social withdrawal and 
aggressive behaviors. These behaviors can be assessed in the social interaction test, that 
measures explorative and social behaviors between pairs of animals in a either familiar or 
unfamiliar environment. 
When the social interaction test was performed, all the authors found an impairment in 
social behaviours after adolescent exposure to cannabinoids (Leweke and Schneider, 
2010; O’Shea et al., 2004, 2006; Realini et al.,2010). 
2.4 Adolescent Cannabis use and psychosis: human studies 
Different longitudinal studies have confirmed that a large intake of cannabis during 
adolescence triggers acute psychosis and may worsen outcomes in established psychosis 
(D’Souza et al 2009, Henquet et al 2005a, Le Bec et al 2009). An increased incidence of 
psychotic symptoms has been demonstrated by Henquet et al. (2005b) in a 4 year follow 
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up study involving young german individuals aged 12-24 years as well as by Ferdinand et 
al (2005) in a 14-year follow-up study of 4–16 year old subjects from the Dutch population, 
indicating that cannabis use predicted future psychotic symptoms in individuals who did 
not have such symptoms before they began using cannabis. Accordingly, McGrath et al. 
(2010), using a sibling pair analysis nested within a prospective birth cohort, showed  that 
early cannabis use is associated with psychosis-related outcomes in young adults. The 
use of sibling pair analysis provides a better control of several potential confounding 
variables, thus making the results more compelling. 
Interestingly, the inverse relationship has also been demonstrated: that is, the presence of 
psychotic symptoms in those who had never used cannabis predicted future cannabis use 
(Dekker et al., 2009). 
The age when cannabis use begins is one of the more important determinant for 
susceptibility to psychotic illness  Cannabis users had an earlier age at onset of psychosis, 
and there was a strong linear relationship between age at first cannabis use and age at 
onset of both prodromal and psychotic symptoms (Dragtet al., 2010; Sugranyes et al., 
2009, Leeson et al 2011). Initiation by the age of 18 years doubled, whereas initiation by 
15 years quadrupled the odds of subsequent psychotic disorders at follow-up at the age of 
26 years (Arseneault et al., 2002). Accordingly, later age at first cannabis use predicted 
earlier cessation of use and this in turn was linked to fewer positive psychotic symptoms 
and days in hospital during the first 2 years (Leeson et al 2011). 
It has been suggested that cannabis abuse may affect brain circuits involved in reward, 
decision making, attention, learning and memory, and behavioural control, all of which are 
still maturing into early adulthood, thus leading to alterations in neurobiology that increase 
psychosis. In this view, the role of the endocannabinoid system in neural development and 
modulation of neurotransmitter systems during adolescence should be better investigated 
to understand the mechanisms contributing to the enhanced vulnerability to psychosis 
observed in adolescent cannabis users. 
Not all young cannabis users develop psychosis, indicating that cannabis use interacts 
with other variables, such as genetic vulnerability (i.e. the COMT Val108Met 
polymorphism) and other environmental factors, finally leading to psychosis onset (Caspi 
et al., 2005; Dominguez et al., 2010; Fergusson et al., 2006; Henquet et al., 2008, 2009; 
Semple et al., 2005). 
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As a whole, data available so far suggest that exposure to cannabis is neither a necessary 
nor a sufficient cause of schizophrenia but, more likely, cannabis exposure is a component 
or contributing cause that interacts with other known (genetic, environmental) and 
unknown factors, culminating in schizophrenia. 
2.5 Alterations of the endocannabinoid system in schizophrenia: animal studies 
CB1 receptor 
Vigano’ et al. (2009) demonstrated that the cognitive impairment induced by repeated PCP 
injections in juvenile rats was associated with a significant enhancement in CB1 receptor 
binding in the amygdala and ventral tegmental area (VTA). Moreover, PCP treatment 
induced a widely distributed decrease in CB1 receptor functionality in the PFC, 
hippocampus substantia nigra and cerebellum and a slight increase in the globus pallidus. 
These results suggest that a maladaptation in CB1 receptor density and functionality could 
be related to the cognitive impairment associated with the glutamatergic hypothesis of 
schizophrenia. Differently, Seillier et al. (2009) using a subchronic PCP model in adult rats 
found no changes in CB1 receptor expression whereas increases in CB receptor/G protein 
coupling in the ACC and nucleus accumbens (NAc) and a reduction in the CA2/3 fields of 
the hippocampus were observed. Differences in drug regimen and the different age of the 
animals might explain the discrepant results. 
Using a rat model based on social isolation, Malone et al. (2008) found a down-regulation 
in CB1 receptor density in the caudate putamen (CPu) and amygdala. In contrast, 
increases in CB1 receptor binding in the PFC, CPu, thalamic nuclei and posterior area of 
the hypothalamus were recently reported by Sciolino et al. (2010) and  Robinson et al. 
(2010), using the same experimental model. The different techniques used, the different 
rat species and the duration of the isolation rearing protocol may account for the observed 
discrepancies. 
CB1 receptor expression and functionality was also studied in another 
neurodevelopmental model of schizophrenia based on the maternal deprivation protocol. A 
long-lasting decrease in CB1 receptor expression was showed in both male and in female 
rats submitted to 24-hour maternal deprivation at PND 9. The down-regulation was evident 
either in the short term (at PND 13) as well as in the long term period (at adulthood) 
(Suarez et al., 2009; Llorente-Berzal et al., 2011), strongly supporting the idea that long-
lasting alterations in the endocannabinoid system are involved in the development of 
schizophrenia-like symptoms. 
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Another important approach to clarify CB1 receptor's role in schizophrenia is the use of 
knockout (ko) mice. Acute PCP administration is known to induce locomotor activation, 
stereotyped behaviors as well as reduced social interactions in wild-type animals. 
Interestingly, PCP-induced behavioral alterations were different in CB1 ko mice (Haller et 
al., 2005), since reduced locomotion, greater enhancement in ataxia and stereotypies as 
well as no alterations in social behavior were observed. These findings indicate that CB1 
gene disruption dramatically affects the behavioral effects of PCP, strongly supporting its 
involvement in schizophrenia. As social disruption and stereotypy are believed to model 
respectively negative and positive symptoms of schizophrenia, it can be tentatively 
suggested that cannabinoids may play different parts in these two symptoms, possibly 
inhibiting positive but facilitating negative ones. 
CB2 receptor 
In the last years, evidence has been accumulated pointing to a role for central CB2 
receptors in schizophrenia. CB2 deletion in mice caused a decreased motor activity, 
enhanced response to acute cocaine, PPI deficit, and cognitive impairment (Ortega-Alvaro 
et al., 2011). This preliminary evidence raises the possibility that a pharmacological 
manipulation of CB2 receptor could be a potential therapeutic target for the treatment of 
schizophrenia-related disorders. 
Endocannabinoid levels 
Besides CB1 and CB2 receptors, there is experimental evidence for an involvement of 
alterations in endocannabinoid levels in schizophrenia. 
Using an animal model based on PCP administration, Vigano’ et al. (2009) found no 
changes in AEA levels in either the PFC and hippocampus, whereas 2-AG content rose 
significantly in the PFC of PCP-treated rats. In contrast, Seillier et al. (2009) measured 
AEA and 2-AG in PCP-treated rats not tested for behaviors and found increases in AEA 
levels in the NAc and VTA and a trend, although not significant, in the PFC whereas 2-AG 
levels were increased only in the VTA. One of the more relevant reason for the 
discrepancy of the above quoted data, both based on PCP injection, is the time of 
endocannabinoids level measurements: immediately after the behavioral test (as in 
Vigano's study) or in animals that had not been tested (as in Seillier's one). Thus, in the 
former case endocannabinoids levels reflect their production in response to neuronal 
activity, in the latter one they reflect basal levels. 
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More recently, a paper of Eisenstein et al. (2010) looked at the role of 2-AG and 
endocannabinoid signaling in rodents with bilateral olfactory bulbectomy (OBX), a 
procedure that induces increased locomotor activity in response to the open field, a 
behavior attributed to hyperdopaminergic activity resembling schizophrenia. OBX-induced 
hyperactivity was restricted to the first 3 minutes of the open field test, showing the 
presence of novelty (0-3min) and habituation (3-30) phases of the locomotor response. 2-
AG and AEA levels were reduced in the ventral striatum in OBX animals. While in sham-
operated the levels of 2-AG were negatively correlated with the distance travelled during 
the novelty phase, in OBX rats 2-AG levels correlated with the distance traveled during the 
habituation phase, strongly support the idea that the endocannabinoid system and, 
particularly, 2-AG are implicated in the hyperactive locomotor response induced by OBX 
and suggest that drugs able to increase 2-AG content can be suggested in human 
disorders modeled by OBX, such as schizophrenia. 
Alterations of the endocannabinoid system triggered by adolescent THC exposure 
As already mentioned above, the adolescent brain appears to be particularly vulnerable to 
the long-lasting adverse effects of cannabinoids, especially THC. In order to analyze the 
molecular underpinnings of this vulnerability, we recently investigated whether and how 
chronic THC exposure interferes with different maturational events occurring in the 
prefrontal cortex during adolescence. In the same experimental model used in the present 
thesis, we found that the endocannabinoid system undergoes maturational processes from 
mid adolescence into adulthood. Adolescent THC exposure disrupts these processes, 
leading to impaired endocannabinoid signaling and deficits in endocannabinoid-mediated 
LTD in the adult prefrontal cortex.  
In this same developmental window, neuronal refinement occurs at prefrontal cortex 
glutamatergic synapses, and adolescent exposure to THC impairs it. THC altered the 
maturational fluctuations of NMDA subunits leading to larger amounts of gluN2B at 
adulthood. Moreover, adult animals pre-exposed to THC showed increased AMPA gluA1 
with no changes in gluA2 subunits. This suggests the presence of more calcium 
permeable AMPA receptors at adulthood, also supported by reduced rectification index for 
AMPA EPSCs.  
This severe effect induced by adolescent THC in the prefrontal cortex might be due to the 
disruption of the physiological role played by the endocannabinoid system during this 
developmental window. Indeed, the blockade of CB1 receptor specifically from early to late 
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adolescence seems to prevent the occurrence of pruning at glutamatergic synapses. Thus, 
vulnerability of adolescent animals to long-lasting THC adverse effects might partly reside 
in the disruption of the pivotal role played by the endocannabinoid system in the 
adolescent prefrontal cortex maturation (Rubino et al. submitted). 
2.6 Alterations of the endocannabinoid system in schizophrenia: human studies 
CB1receptor 
Several lines of evidence support the presence of alterations in CB1 receptors in the brain 
of schizophrenic patients. Up-regulations of CB1 receptors have been demonstrated in the 
dorsolateral prefrontal cortex (DLPFC), ACC and posterior cingulated cortex (PCC) of 
schizophrenic patients (Dean et al., 2001; Zavitsanou et al., 2004; Newell et al., 2007). In 
contrast, Eggan et al. (2008) showed a down-regulation of CB1 mRNA levels in the 
DLPFC of subjects with schizophrenia that was significantly correlated with a reduction in 
glutammic acid decarboxilase and cholecystokinin mRNA levels in the same brain region. 
Finally, no changes in the superior temporal gyrus and ACC have been found by Deng et 
al. (Deng et al., 2007) and Koethe et al. (2007) respectively. Moreover, Uriguen et al. 
(2009) showed that the immunodensity of CB1 receptors was significantly decreased in 
antipsychotic-treated subjects but not in drug-free schizophrenic subjects. Both cannabis 
consumption and treatment with antipsychotic drugs as well as  the different techniques 
used for determining CB1 receptor levels could explain the apparent inconsistent results 
obtained in these studies. More recently, Dalton et al. (2011), employing a more rigorous 
control for potentially confounding factors, reported a significant increase in CB1 receptor 
binding in the DLPFC in a subgroup of patients who suffered from paranoid schizophrenia 
compared to normal controls and patients with non-paranoid schizophrenia. This finding 
suggests a different contribution of the endocannabinoid system in different subtypes of 
schizophrenia, arguing for distinct neurochemical correlates of clinical subtypes and 
raising the possibility of instituting psychopharmacological treatment accordingly. 
Finally, a recent Positron Emission Tomography (PET) study showed an elevated binding 
of a specific CB1 tracer in the pons of schizophrenic patients (Wong et al., 2010). More 
importantly, this study suggested that CB1 binding is positively associated with severity of 
positive symptoms and negatively with severity of negative symptoms. 
As a whole, human studies highlight the presence of CB1 receptor dysregulations in 
specific brain areas mainly involved in cognition and memory, two functions highly 
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compromised in schizophrenia. Importantly, variation in the CB1 receptor gene may confer 
risk for disorganized schizophrenia (Chavarría-Siles et al., 2008). 
CB2 receptors 
To date, there is little clinical evidence supporting a role for CB2 receptors in 
schizophrenia. In  2003, De Marchi et al. (2003) showed that decreased AEA and CB2 
receptor mRNA levels in peripheral blood mononuclear cells were associated with a 
clinical remission of schizophrenia. Moreover, a close correlation between a polymorphism 
of the CB2 receptor gene and increased susceptibility to schizophrenia has been 
demonstrated (Ishiguro et al., 2010). More recently, Minocci et al. (2011), in a case–control 
study, found a significant association between bipolar disorders and a polymorphism in 
CB2 receptor gene, supporting the hypothesis that CB2 is involved in the pathogenetic 
mechanism underlying this affective disorder and, presumably, other psychotic diseases. 
Endocannabinoid levels  
Besides alterations in the CB1 receptor, clinical studies show that also changes in 
endocannabinoid levels are implicated in schizophrenia. De Marchi et al. (2003), 
measuring AEA levels from blood of volunteers or patients with schizophrenia, found 
significantly more AEA in schizophrenic patients, and clinical remission was accompanied 
by a significant drop in the levels of AEA and the mRNA transcript for CB2 receptors and 
FAAH. Thus, endocannabinoid signaling might be altered during the acute phase of 
schizophrenia not only in the central nervous system but also in the blood. These 
researchers suggested that the observed changes might be related to the immunological 
alterations described in schizophrenia. 
Leweke et al. (1999) and Giuffrida et al. (2004) reported a significant increase of 
cerebrospinal AEA levels in acutely schizophrenic antipsychotic naïve patients which was 
not observed in patients suffering from affective disorders or dementia. Differently from the 
work of De Marchi et al. (2003), no changes in AEA content were observed in serum 
(Leweke et al., 1999), suggesting that the changes in AEA levels were presumably of 
central origin. Other lipid molecules, such as oleoylethanolamide (OEA) and 
palmitoylethanolamide (PEA), were not altered in schizophrenics, thus excluding any 
generalized alteration in lipid signaling. 
The negative correlation between cerebrospinal AEA levels with psychopathological 
symptoms in acute, non-medicated, schizophrenic patients suggests the existence of an 
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“anandamidergic” dysregulation in schizophrenia. In this context, AEA might play an 
adaptive role, counteracting the neurotransmitter abnormalities in acute schizophrenia. 
Moreover, patients treated with atypical antipsychotics, did not differ from antipsychotic-
naive schizophrenic individuals with respect to cerebrospinal AEA, whereas patients 
receiving preferentially D2 receptor-blocking antipsychotic medication had AEA levels 
comparable to healthy volunteers. This is consistent with the theory that “typical” 
antipsychotics normalize AEA levels by blocking D2-like receptors that initiate AEA 
synthesis in limbic and motor areas, while “atypical” preferentially interact with serotonin 5-
HT2A receptors. In a hypothetical model of the pathophysiological relevance of the 
endocannabinoid system, binding of endogenous agonists like AEA or 2-AG to CB1 
receptors counteracts increased dopaminergic neurotransmission. This mechanism might 
be protective because as above quoted, levels of AEA in cerebrospinal fluid of 
schizophrenic patients were inversely correlated  with the severity of psychotic symptoms 
(Giuffrida et al., 2004). Finally, Koethe et al. (2009) investigated the levels of AEA and 
OEA in cerebrospinal fluid and serum of patients with initial prodromal states of psychosis. 
AEA levels in the cerebrospinal fluid were significantly elevated in these patients, in a 
manner comparable to that described for first-onset, antipsychotic-naïve, schizophrenic 
subjects whereas OEA concentrations did not differ significantly between patients and 
controls, thus ruling out the possibility that changes in AEA levels were caused by a 
generalized alteration in ethanolamide signaling. 
3. Pharmacological modulation of the endocannabinoid system as therapeutic tool 
for schizophrenia 
Several preclinical studies have been published in the last ten years to clarify the effect of 
a pharmacological modulation of CB1 receptors (through agonists, antagonists and 
indirect agonists) on schizophrenia-like symptoms. In contrast, human  data on the effect 
of cannabinoid drugs in schizophrenia are limited to cannabidiol (CBD, a non-psychoactive 
phytocannabinoid) and rimonabant, a CB1 receptor antagonist/inverse agonist. 
3.1 Animal studies 
Hyperlocomotion and stereotipy 
Several papers reported the effects of both acute and chronic manipulation of the 
endocannabinoid system on hyperlocomotion and stereotypies induced by 
psychotomimetic agents. The majority of these studies highlights the ability of both natural 
and synthetic cannabinoid agonists to reduce locomotor activation induced by 
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amphetamine (Gorriti et al., 1999; Long et al., 2009), cocaine (Przegalinski et al., 2005) 
and quinpirole (Marcellino et al., 2008) in rats. In contrast, Gorriti et al. (2005) and Moreno 
et al. (2005) showed that THC and HU-210 exacerbated quinpirole-induced 
hyperlocomotion in rats whereas CP-55,940 administration had no effect on amphetamine-
induced locomotor activation in monkeys (Madsen et al., 2006). Very different doses and 
regimens of both cannabinoid agonists and psychotomimetic agents were used, and this 
could explain the discrepant results obtained. However, the reported improvement of 
positive symptoms following cannabinoid agonists administration agrees with the 
hypothesis of a protective role of AEA in schizophrenia (Giuffrida et al., 2004). 
Interestingly, the AEA transport inhibitor, AM404, reversed apomorphine- and quinpirole-
induced stimulation of motor behaviors (Beltramo et al., 2000). Accordingly, unpublished 
data from our laboratory demonstrated that indirect enhancement of AEA levels, through 
URB597 and AM404 injections, recovered PCP-induced hyperlocomotion and stereotyped 
behaviors in rats (Rubino et al., unpublished observations). 
Also the potential anti-psychotic action of the non-psychoactive component of Cannabis 
sativa, CBD, has been investigated. Both acute and chronic administration of this 
cannabinoid compound have been proven to reduce hyperlocomotion induced by 
dopaminergic and glutamatergic agents in rodents (Gururajan et al., 2011; Long et al., 
2009; Moreira and Guimaraes, 2005; Zuardi et al., 1991). As a general comment, 
cannabinoid agonists can differently modulate hyperlocomotion and stereotipy improving, 
exacerbating or having no effect on these behaviors. The protective effect strengthens 
Giuffrida’s hypothesis of the protective role of AEA whereas an excessive stimulation of 
CB1 receptors could reduce the inhibitory control of the endocannabinoid system on 
dopaminergic functions (through receptor desensitization) thus worsening the symptoms. 
Confounding data have been reported on the effect of cannabinoid antagonists 
administration on schizophrenia-like symptoms. In fact, administration of the CB1 
antagonist/inverse agonist, rimonabant, either augmented (Ferrer et al., 2007; Masserano 
et al., 1999; Thiemann et al., 2008), attenuated (Cheer et al., 2007; Poncelet et al., 1999; 
Tzavara et al., 2003; 2009) or unaltered (Gerdeman et al., 2009; Lesscher et al., 2005; 
Madsen et al., 2006; Martin et al., 2003) locomotor responses or stereotyped behaviors 
induced by dopaminergic agents. In contrast, results obtained with the CB1 receptor 
antagonist, AM251, appear to be less ambiguous, since its administration was effective in 
reducing the psychomotor effect induced by amphetamine (Seillier et al., 2010; Thiemann 
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et al., 2008) or A2A receptor antagonists (Lerner et al., 2010) in rodents. Interestingly, the 
effect of cannabinoid antagonists on psychomotor activation was reported to be mediated 
by the selective blockade of CB1 receptors in the nucleus accumbens core (Morra et al., 
2010), but not shell (Chiang and Chen, 2007). The protective effect of CB1 receptor 
blockade is supported by data demonstrating that genetic inactivation of CB1 receptors 
reduced hyperlocomotion induced by amphetamine, PCP and SCH442416, a A2A 
receptor antagonist (Corbillè et al., 2007; Haller et al., 2005; Lerner et al., 2010). 
However, the protective effect of CB1 receptor antagonists are often limited to habituated 
animals and needs further investigation. 
Social behaviors 
Self-administration of WIN 55,212-2 has been reported to prevent the social deficit induced 
by chronic intermittent PCP in adult rats (Spano et al., 2010). PCP-induced social 
withdrawal was reversed also by enhancement of the endocannabinoid tone through 
URB597 or OMDM-2 (Seillier et al., 2010), suggesting that CB1 receptor activation may 
exert a protective action on PCP-induced reduction in sociability. Also CBD has been 
proven to prevent social withdrawal induced by glutamatergic agents (Long et al., 2006; 
Gururajan et al., 2011). Surprisingly, a potential benefit deriving from CB1 receptor 
blockade was also demonstrated by the study of Haller et al. (2005) showing that genetic 
CB1 receptor disruption prevented PCP-induced social deficit in mice. 
Cognitive deficits 
Cannabinoids have been reported to produce transient cognitive impairments including 
deficits in learning, short-term memory, working memory, executive function and attention 
in both human (Sewell et al., 2010) and animals (Zanettini et al., 2011). However, so far 
only few studies examined the effect of a pharmacological modulation of the 
endocannabinoid system on cognitive deficits in animal models of schizophrenia. Chronic 
THC treatment worsened PCP-induced cognitive impairment in the novel object 
recognition test (Vigano et al., 2009). In contrast, Spano et al. (2010) showed that WIN 
55,212-2 self-administration in adult rats prevented PCP-induced deficits in recognition 
memory. These opposite results could be related to the different properties of THC and 
WIN 55,212-2 at CB1 receptors as well as the different ages at cannabinoid treatment, 
since younger animals (Vigano et al., 2010) display different vulnerability to aversive 
stimuli. In Vigano’s work, the observed reduction of cognitive functions in THC-treated rats 
was accompanied by a marked decrease in AEA levels, suggesting that reduced AEA 
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content could represent one of the molecular mechanisms underlying the worsening of 
cognitive performances. This hypothesis is further confirmed by the work of Seillier et al. 
(2010) demonstrating that enhancement of AEA levels, through URB597 administration, 
reversed PCP-induced cognitive deficit. 
Concerning CB1 receptor antagonists, AM251 was shown to ameliorate the working-
memory deficit in PCP-treated rats (Seillier et al., 2010). In agreement, our recent work 
(Guidali et al., 2010) supported the beneficial effect of chronic AM251 treatment on 
cognitive performance in the novel object recognition test in a pharmacological model of 
schizophrenia. More recently, another CB1 receptor antagonist, AVE1625, was reported to 
improve both working and episodic memory impairments induced by MK-801 or neonatal 
nitric oxide synthase inhibition in rodents (Black et al., 2011), further suggesting that CB1 
receptor antagonist may be useful to treat the cognitive deficits in schizophrenia. 
Sensorimotor gating 
PPI response can be disrupted in animals through various experimental conditions such as 
pharmacological manipulation of different transmitter systems as well as exposure to 
adverse environmental conditions such as social isolation and psychosocial stress. The 
effects of cannabinoid agonists on PPI disruption induced by either pharmacological and 
non-pharmacological conditions appear to be confounding and inconclusive. WIN55212-2 
administration attenuated PCP-induced disruption of PPI (Spano et al., 2010) but led to a 
significant improvement of PPI in psychosocially stressed rats (Brzozka et al., 2011). In 
contrast, Malone and Taylor (2006) demonstrated that THC disrupted PPI response in 
socially isolated rats. Finally, THC improved PPI response in NRG1 mutant mice, a genetic 
model for schizophrenia (Boucher et al., 2007). Thus, depending on the doses of 
cannabinoid agonists, duration of administration, environmental conditions used or 
animals’ genetic background, cannabinoid administration can evoke opposite effects in 
PPI response. 
Controversial findings have been reported also with the non-psychoactive cannabinoid, 
CBD. Long et al. (2006) showed that in mice CBD significantly reversed PPI deficits 
induced by MK-801, suggesting an antipsychotic potential of this compound. However, this 
finding was not replicated by Gururajan et al. (2011) who demonstrated that CBD could not 
recover MK-801-induced disruption of PPI. It is worth to note that in these two studies 
different animal models (mice/rats) and experimental conditions (number and duration of 
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behavioral testing) were used, thus explaining at least in part the reported contradictory 
findings. 
Finally, Mansbach et al. (1996) showed that the CB1 receptor antagonist SR141716 did 
not reverse the PPI disruption induced by both dopaminergic and glutamatergic agents. 
This finding was not confirmed by later studies demonstrating the ability of CB1 receptor 
antagonists to reverse the decrease in PPI induced by both pharmacological and 
environmental conditions. Ballmaier et al. (2007) reported that SR141716 and AM251 
acted as antipsychotic compounds reversing PCP- and MK-801-induced disruption of PPI 
in rats. More recently, Black et al. (2011) showed the ability of another CB1 receptor 
antagonist AVE1625 to reverse LI induced by MK-801. Similarly, Malone et al. (2004) 
demonstrated that SR141716 antagonized the disruptive PPI effects of apomorphine also 
in mice. When SR141716 was tested in social isolated rats, Malone and Taylor (2006) 
found that its administration only reversed the decrease in PPI induced by THC but failed 
to recover the isolation-induced reductions in PPI, indicating that THC-induced disruption 
of PPI depend on activation of CB1 receptors but antagonism of CB1 receptors is probably 
not enough to normalize the PPI disruption induced by developmental manipulations. As a 
whole, CB1 receptor antagonists reversed the PPI disruption induced by pharmacological 
agents (cannabinoid drugs included) whereas their administration failed to recover the PPI 
deficit induced by adverse environmental conditions. 
Recently, as above reported, PPI response has been reported to be disrupted in CB2 ko 
mice (Ortega-Alvaro et al., 2011), suggesting that CB2 receptor activation could represent 
a promising target for the rescue of PPI deficits. 
3.2 Human studies 
So far, only the potential therapeutic applications of CBD and rimonabant have been 
investigated. 
CBD was effective in attenuating psychotic symptoms induced by nabilone and ketamine 
in healthy individuals (Leweke et al., 2010; Bosi et al., 2003). A recent fMRI trial observed 
that THC and CBD activated in opposite ways different brain areas in response to different 
tasks and, moreover, CBD treatment prevented the acute induction of psychotic symptoms 
by THC (Bhattacharyya et al., 2010). However, a recent study of Hallak et al. (2010) 
investigated the effects of CDB on selective attention and on the pattern of electrodermal 
responsiveness to auditory stimuli in patients and observed no significant beneficial effect 
of acute CBD administration, suggesting that a single CBD injection may not be sufficient 
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to induce an improvement of cognitive functioning. The absence of  toxic effects 
associated with CBD, made its chronic administration acceptable in human trials. In line 
with this, a pilot study by Zuardi et al. (1995) demonstrated that a 19-year old female 
diagnosed with schizophrenia treated for four weeks with increasing doses of CBD showed 
a significant improvement of the Brief Psychiatric Rating Scale (BPRS) similar the one 
produced by haloperidol but avoiding the severe side effects after treatment with the 
conventional antipsychotic. In 2006, the study was expanded to three male subjects with 
22 and 23 years of age, diagnosed with schizophrenia resistant to the treatment with 
conventional antipsychotics (Zuardi et al., 2006). Increasing doses of CBD failed to induce 
a significant improvement of BPRS in two of the subjects whereas the third did not 
respond to CBD at all. The lack of beneficial effect of CBD in these patients may be 
ascribed to their clinically resistance to antipsychotics. Later on, the potential antipsychotic 
properties of CBD were investigated by using a four-week exploratory, double-blind, 
controlled trial, with forty-two subjects (Leweke et al., 2007). In this study, CBD was tested 
in patients diagnosed with schizophrenia compared with the atypical antipsychotic 
amisulpride. Both CBD and amisulpride induced a significant reduction of psychotic 
symptoms but CBD induced significantly less side effects compared to the atypical 
antipsychotic used. Interestingly, CBD has been proven to be effective in alleviating 
psychotic symptoms associated with other neuropsychiatric conditions, such as Parkinson 
disease (Zuardi et al., 2009). 
Although with the limitation due to the restricted number of subjects used in the studies, 
these preliminary findings point to a potential exploitation of CBD in the treatment of 
psychosis, particularly because of  its safety and tolerability compared to traditional 
antipsychotics. However, long-term, double-blind, placebo-controlled trials in larger 
samples of subjects are strictly necessary to clearly address this issue. 
Rimonabant has been used in several countries for treating obesity and, before being 
removed from the market because of its severe adverse effects (Ugur et al., 2008), it was 
tested in some psychiatric conditions with promising results. Based on the possibility that a 
hyperactivity of the endocannabinoid system in schizophrenia could be related to the 
development of clinical symptoms, rimonabant was tested in a six-week, double-blind 
controlled trial in schizophrenic patients (Meltzer et al., 2004). Contrary to expectations, 
rimonabant did not improve the Positive and Negative Syndrome Scale total score, CGI 
severity of illness score, BPRS scores compared to the group receiving placebo. More 
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recently, Kelly et al. (2011) conducted a sixteen-week, double-blind, placebo-controlled 
study with rimonabant in people with schizophrenia or schizoaffective disorder, based on 
the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria, who 
were clinically stable on second-generation antipsychotics. They found a significant 
improvement in BPRS total score in the rimonabant group compared with the placebo 
group. A major limitation of this study is the small sample size, due to its premature 
termination (rimonabant marketing was suspended in 2008), and consequent limited 
power to detect efficacy or rare adverse events. Nonetheless, rimonabant was well 
tolerated and was not associated with worsening of psychiatric symptoms, thus CB1 
inverse agonism/antagonism remains a promising approach for pharmacotherapy of 
schizophrenia. 
In conclusion, it can be stated that the cannabinoid system is a promising target for novel 
therapeutic interventions in schizophrenia. However, additional controlled trials are still 
required to confirm the possible therapeutic exploitation and determine the safety of 
cannabinoid compounds. Moreover, besides CBD and rimonabant, other 
phytocannabinoids, such as cannabigerol (CBG), tetrahydrocannabivarin (THCV), 
cannabidivarin (CBDV), or the association of THC and CBD, which is already used in 
some neurological disorders, can represent promising approach for treating psychotic 
disorders. 
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Objectives and hypotheses 
The studies described in this thesis were designed with the intent to shed light on the 
complex relationship between cannabis, the endocannabinoid system and schizophrenia, 
taking into account both the exogenous and the endogenous cannabinoid hypothesis of 
schizophrenia. 
The first approach is based on our recent demonstration that chronic THC treatment in 
adolescent  rats induces permanent alteration in the endocannabinoid system and aims at 
verifying if dysregulations of the endocannabinoid system can affect the correct maturation 
of other neurotransmitter system, specifically the GABAergic system, thus favoring the 
appearance of a psychotic-like phenotype in adulthood . 
The second part of this thesis highlights the presence of alterations of the 
endocannabinoid system in a validated neurodevelopmental model of schizophrenia and  
suggests that the pharmacological modulation of this system might represent a promising 
tool for treating schizophrenia. 
With that said, the aims of the present PhD project were as follows. 
Aim of study n. 1 
“Adolescent delta-9-tetrahydrocannabinol (THC) exposure as a risk factor for 
schizophrenia” 
The aim of this study was to assess whether adolescent exposure to delta-9-
tertrahydrocannabinol (THC), the main psychoactive component of Cannabis sativa, is 
associated with an increased vulnerability to develop psychotic symptoms in adult female 
rats. 
In order to answer this question, the following points were examined: 
- The behavioral phenotype present in adult female Sprague-Dawley rats after 
adolescent THC exposure was characterized through a series of behavioral tests 
measuring specific endophenotypes of schizophrenia in animals. Specifically, 
cognitive deficits were assessed in terms of recognition memory, negative-like 
symptoms in terms of social behavior and behavioral despair, whereas sensitization 
to phencyclidine (PCP)-induced hyperlocomotion and stereotypy was determined as 
a measure of positive-like symptoms. 
- The impact of adolescent THC exposure on the GABAergic transmission in the 
adult prefrontal cortex (PFC) and its possible involvement in the development of the 
observed behavioral phenotype were assessed.. 
Aim of study n. 2 
 “Modulation of the endocannabinoid system as potential antipsychotic strategy” 
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The aims of this study was to investigate the effect of a pharmacological manipulation of 
the endocannabinoid system by acute and chronic treatment with a CB1 receptor 
antagonist, AM251, on schizophrenia-like symptoms produced by a neurodevelopmental 
animal model of schizophrenia based on the social isolation procedure. 
To this aim, the following points were examined: 
- The goodness of the isolation rearing protocol was assessed in male Lister Hooded 
rats after 5 weeks of post weaning social isolation before performing other 
behavioral and neurochemical analyses. Therefore, behavioral analyses were 
performed in order to check for the presence of schizophrenia-like symptoms such 
as hyperlocomotion in a novel environment, cognitive impairment, aggressive 
behaviors in the social interaction test and PPI responses. 
- The presence of changes in CB1 receptor density and functionality as well as 
endocannabinoid levels was monitored following the isolation rearing procedure in 
specific brain regions in order to highlight a possible contribution of imbalances in 
the endocannabinoid system to the development of schizophrenia-like traits in 
isolated animals. Moreover, the presence of alterations in dopamine D1 and D2 and 
glutamate NMDA receptor densities was analyzed in different brain areas following 
post-weaning social isolation. 
- The ability of acute and chronic treatment with a selective CB1 receptor 
antagonist/inverse agonist, AM251,  to reverse schizophrenia-like symptoms in 
isolation reared rats was investigated. 
- The effect of AM251 treatment on the  isolation-induced alterations of biochemical 
parameters (endocannabinoid system, dopamine and NMDA receptor densities) 
was examined to find a possible neural substrate of the improved phenotype. 
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1) Methods in Study n.1 
Animals 
Female Sprague Dawley rats aged 28 days at the time of arrival were obtained from 
Charles River laboratories (Calco, Italy) and were housed in clear plastic cages on a 12 
hour light-dark cycle (lights on 08:00h) and in a temperature (22 ± 2°C) and humidity 
controlled environment (50±10%). All animals were allowed free access to food and water. 
All experiments took place during the light phase and were performed in accordance with 
the guidelines released by the Italian Ministry of Health (D.L.116/92) and (D.L.111/94-B), 
and the European Community directives regulating animal research (86/609/EEC). All 
efforts were made to minimize the number of animals used and their suffering. 
Adolescent THC Treatment 
Delta-9-tetrahydrocannabinol (THC), a generous gift from GW Pharmaceutical (Salisbury, 
UK), was further purified to reach THC concentrations as high as 90% and dissolved in 
ethanol, cremophor and saline (1:1:18). Rats were injected with increasing doses of THC, 
or vehicle, twice a day from PND 35 to PND 45 (2.5mg/kg, PND 35-37; 5mg/kg, PND 38-
41; 10mg/kg, PND 42-45), according to our previous published protocol (Rubino et al, 
2008) (Fig. 1A). This protocol resembles a heavy use of marijuana, inasmuch as, 
according to the transformation in human equivalent dose proposed by FDA and the 
average content of THC in a joint, our first dose roughly corresponds to one joint, the 
second one to two joints, and the higher one to four joints. These moderate to high doses 
were chosen to be within the range known to produce behavioral effects in rats. Animals 
were then left undisturbed till adulthood. At PND 75 the behavioral effect triggered by 
adolescent THC were compared to those induced by sub-chronic administration of the 
non-competitive NMDA receptor antagonist, phencyclidine (PCP) (Neill et al, 2010). 
Sub-chronic PCP treatment in adult animals 
Sub-chronic PCP administration is known to mimic the cognitive impairment and some 
negative-like symptoms of schizophrenia, such as social withdrawal and behavioral 
despair, even after long-term withdrawal (Enomoto et al. 2007; Mouri et al., 2007). 
Phencyclidine hydrochloride (PCP, Sigma-Aldrich, UK) was dissolved in saline and 
administered at a dose of 5 mg/kg (volume of injection 1 ml/kg), i.p. 
Animals were treated with either saline or PCP once a day for 7 days, according to a 
treatment schedule slightly modified from Seillier et al. (2010) and reported in Fig. 1B. 
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Acute PCP administration in THC pre-treated rats 
Sensitization to hyperlocomotion and stereotyped behaviors induced by acute PCP 
administration is widely recognized as another endophenotype of schizophrenia in rodents. 
In order to determine whether adolescent THC exposure could sensitize to the locomotor-
activating effects of acute PCP administration, at PND 75, THC- and vehicle-treated rats 
received an acute injection of PCP (or saline) at the dose of 2.5 mg/kg (Fig. 1C) and their 
behavior in terms of locomotor activation and stereotyped behaviors was monitored for 50 
minutes after the injection. 
Behavioral Tests 
Classic and spatial versions of the novel object recognition (NOR) test 
The experimental apparatus used for the object recognition test was an open-field box (43 
x 43 x 32 cm) made of Plexiglas, placed in a dimly illuminated room. Animals performed 
each test individually. The experiment was performed and analyzed as previously 
described (Realini et al, 2011; Zamberletti et al, 2012). Briefly, each animal was placed in 
the arena and allowed to explore two identical previously unseen objects for 5 minutes 
(familiarization phase). After an inter-trial interval of 3 minutes one of the two familiar 
objects was replaced by a novel, previously unseen object and rats were returned to the 
arena for the 5-minute test phase. In the spatial variant of the test, both novel and familiar 
objects were placed in different positions compared to the familiarization phase, that is a 
spatial cue was added in the test. During the test phase the time spent exploring the 
familiar object (Ef) and the new object (En) was videotaped and recorded separately by 
two observers blind to the treatment groups and the discrimination index was calculated as 
follows : [(En-Ef)/(En+Ef)] x 100 
Social Interaction Test 
The test was carried out as previously reported (Realini et al, 2011; Zamberletti et al, 
2012). On the day of testing, each animal was habituated for 10 minutes in the test arena 
(60 x 60 x 60 cm), an open-field box made of Plexiglas. During the test session, each 
animal was allowed to freely explore an unfamiliar congener in the arena for 10 minutes 
and we recorded the time spent in social behaviors and the number of aggressive 
behaviors. Social behaviors were defined as sniffing, following, grooming, mounting and 
nosing. Aggressive behaviors were defined as attacking, biting, tail rattling and aggressive 
grooming. 
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Forced Swim Test (FST) 
Animals were tested in a modified version of the FST with only the first session of 
swimming as previously reported (Realini et al, 2011; Zamberletti et al, 2012), to measure 
a preexisting behavioral deficit induced by the behavioral manipulation. Briefly, rats were 
forced to swim for 15 minutes inside a clear 50 cm tall, 20 cm diameter glass cylinder filled 
to 30 cm with 25°C water. The session was videotaped for later analysis of the following 
parameters: immobility (time spent by the animal floating in the water making only those 
movements necessary to keep its head above the water), swimming (active swimming 
movements to the center of the cylinder), climbing (forceful thrashing movements with 
forelimbs against the walls of the cylinder). The time spent in each of these behaviors was 
measured by an experimenter blind to the treatment groups. 
Locomotor activity and stereotyped behaviors 
Rats were placed in a computer-controlled infra-red activity monitor arena. The arena 
consisted of a clear acrylic box, 43×43×32 cm (Ugo Basile, Varese, Italy) placed in a 
sound-attenuating room and fitted with two parallel infrared beams, located 2 and 6 cm 
from the floor to measure horizontal movement. Each animal was habituated in the arena 
for 10 minutes and then injected with acute PCP or vehicle. After the injection, horizontal 
movement and stereotyped behavior were recorded for 50 minutes (five 10-minute trials) 
and analyzed by two observers blind to the treatment groups. Stereotyped behavior was 
defined as episodes of repetitive licking, stereotyped searching, side-to-side waving or 
turning, dorso-ventral head movements, frequent repetitive rearing, forepaw flattering and 
repetitive gnawing. 
Biochemical analyses 
Biochemical investigations were performed in animals not tested for behavior. For 
histochemical analyses, rats were deeply anaesthetized with a 400 mg/kg dose of chloral 
hydrate and then perfused with 4% paraformaldehyde (PFA). For c-Fos detection brains 
were collected 20 minutes after acute PCP injection. Following extraction, brains were 
stored at 4°C in 4% PFA for 24 h and cryoprotected in 30% sucrose for a minimum of 24 h. 
Brains were included in OCT, cut in 40 µm-thick sections using a cryostat and stored at -
20°C in anti-freezing solution (30% glycerol, 30% etylenglycol, 0.02% sodium azide in 
PBS). 
Histochemical analyses 
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For GAD67 staining, slices were incubated in PBS 1x for 10 minutes at 95°C for antigen 
retrieval whereas no antigen retrieval was necessary for cFos staining. After blocking 
peroxidase activity with 3% H2O2 for 15 minutes, sections were incubated in blocking 
buffer (10% normal goat serum, 0.5% Triton X-100 in PBS) for 1 hour at room temperature 
and then incubated with rabbit polyclonal anti-cFos antibody (1:50, Abcam, UK) or  mouse 
anti-GAD67 antibody (1:500, Millipore, Italy) in blocking solution overnight at 4°C. After 
washing, sections were incubated with the biotinylated goat anti-rabbit, or goat anti-mouse 
secondary antibody (1:200; Millipore, Italy) for 1 hour at room temperature. Labelled cells 
were visualized using the ABC system (Vectastain Elite; Vector Laboratories) with 3,3’-
diaminobenzidine as chromogen. The sections were then mounted onto gelatine-coated 
slides, dehydrated and coverslipped with DPX. To control for specificity of immunostaining, 
some sections were processed without the primary antibody. Positive neurons were 
counted as previously described by Guidali et al. (2011), using Image Pro Plus 7.0 
(MediaCybernetics, USA). 
For double immunofluorescence, the sections were processed for antigen retrieval, pre-
incubated in blocking solution for 2 hours at room temperature and then incubated with 
anti-GAD67 primary antibody together with parvalbumin (rabbit anti-parvalbumin, 1:1000, 
Abcam, UK) or cholecystokinin (rabbit anti-cholecystokinin, 1:200, Santa Cruz 
Biotechnology, Santa Cruz, CA) overnight at 4°C. Double immunofluorescence was 
revealed by incubation in a mixture of Alexa Fluor 488 goat anti-mouse and Alexa Fluor 
594 goat anti-rabbit (Invitrogen, Eugene, OR) diluted 1:2000 in blocking solution for 2 
hours at room temperature. After several washes in PBS, sections were mounted onto 
Superfrost slides, dehydrated and coverslipped with ProLong Gold antifade reagent with 
DAPI (Invitrogen, Eugene, OR). 
Digital Images were captured using a Olympus DP50 camera attached to an Olympus 
BX51-P polarizing/light microscope. Viewfinder Lite 1.0.135 software was used to import 
images from the camera. The quantification was carried out by first delineating the brain 
sections and the regions of interest (ROI) at low magnification (x4 objective). The ROI 
outlines were further refined under a x40 objective and labelled cells were then counted 
manually within the ROI using a 300x300 μm grid as reference and expressed as 
cells/mm2. For each animal, positive cells were counted in four  50μm-sections coursing 
the PFC (bregma +3.10 to 2.50 mm). Counts were determined for each hemisphere 
individually, and an average value for both hemispheres of each section was calculated. 
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To validate siRNA silencing, GAD67 labeled cells were counted within the ROI 
surrounding the site of injection in four  50μm-sections coursing the PFC. For double 
immunofluorescence analysis, four sections per rat were analysed and digital images were 
merged and adjusted only for contrast and brightness using Adobe Photoshop 5.0. Co-
localization was defined by the experimenter as any overlapping staining. The investigator 
was blind to the grouping while taking the photomicrographs and performing the image 
analysis. Quantification was manually determined using Image-Pro Plus 7.0 software 
(Media Cybernetics, Bethesda, MD, USA) and expressed as the percentage of GAD67 
and PV or CCK double positive cells among the total number of PV or CCK positive cells. 
Western blot analyses 
For western blot analyses, rats were decapitated and brains quickly removed. The cerebral 
areas (PFC and hippocampus) were obtained by regional dissection on ice, immediately 
frozen in liquid nitrogen and stored at -80°C until processing. 
For total protein lysate, each brain region was homogenized in an appropriate volume of 
ice-cold buffer (10 mM Hepes pH 7.5, 1.5 mM MgCl2, 10 mM KCl, 2 mM DTT, 1 mM 
PMSF, 1 mM EDTA, 1 mM EGTA, 2 mM sodium orthovanadate, 50 mM NaF, 10 mM 
sodium pyrophosphate, 0.5% Triton, 5 µg/ml aprotinin, and 5 µg/ml leupeptin) and 
centrifuged at 13000 rpm at 4°C for 3 minutes. The supernatant was used as total protein 
lysate and protein concentrations were determined according to the Micro-BCA assay kit 
(Pierce, Rockford, IL). 
Protein lysates were prepared in boiling sodium dodecyl sulphate (SDS) sample buffer and 
equal amounts (30 µg) of total protein were run on a 10% SDS-polyacrylamide gel (15% 
for parvalbumin detection). The proteins were then transferred to polyvinylidene difluoride 
(PVDF) membranes, blocked for 2 h at room temperature in 5% dry skimmed milk in 
TBS1x 0.1% tween20 before incubation overnight at 4°C with the primary antibody. The 
following primary antibodies were used: mouse monoclonal anti-GAD67 (1:5000; Millipore, 
Italy), rabbit polyclonal anti-parvalbumin (1:7000; AbCam, UK), mouse monoclonal anti-
VGAT (1:1000; Synaptic Sistems, Gottingen, Germany) and rabbit polyclonal anti-
cholecystokinin (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA).  Bound antibodies 
were detected with horseradish peroxidase (HRP) conjugated secondary anti-rabbit or 
anti-mouse antibody (1:5000-15000; Chemicon International, Temecula, CA) for 1 hour at 
room temperature and and visualized using ECL Western Blotting Detection Reagents (GE 
Healthcare, UK). For detection of beta-actin, the blot was stripped with Restore Western 
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Blot Stripping Buffer (Thermo Scientific, Rockford, IL) and re-blotted with anti-beta-Actin 
antibody anti-beta-actin monoclonal antibody (1:15000-60000; Sigma Aldrich, Italy) 
overnight at 4°C and visualized as described. Bands were detected by autoradiography. 
For densitometry, images were digitally scanned and optical density of the bands was 
quantified using Image Pro Plus 7.0 software (MediaCybernetics, USA) and normalized to 
control. To allow comparison between different autoradiographic films, the density of the 
bands was expressed as arbitrary units. 
Microdialysis experiments 
Surgery 
On the day of surgery, the animals, kept under isoflurane anaesthesia (1.5% mixture of 
isoflurane and air), were mounted in a David Kopf stereotaxic frame (Tujunga, CA, USA) 
with the upper incisor bar set at -2.5 mm below the interaural line. After exposing the skull 
and drilling a burr hole, a microdialysis probe of concentric design (CMA 12, MW cutoff 
20,000 daltons; outer diameter 0.5 mm, length of dialyzing membrane 2 mm; Alfatech 
S.p.A., Genova, Italy) was implanted into the dorsal striatum (coordinates relative to the 
bregma were: AP: 0.7 mm anterior to bregma, L: 2.8 mm from the midline, V: -5.6 mm 
below the dura) or the PFC (coordinates relative to bregma were AP: 3.2 mm anterior to 
bregma, L: 0.6 mm from the midline, V: -2.2 mm below the dura) (Paxinos & Watson, 
1986). After the implantation, the probe was permanently secured to the skull with 
methacrylic cement and 36 hours later microdialysis was performed in the awake freely 
moving rats. 
Experimental protocol 
On the day of the microdialysis experiment, the probe was continuously perfused with 
Ringer solution (in mM: NaCl, 144; KCl, 4.8; MgSO4, 1.2; CaCl2, 1.7) at a constant flow 
rate of 2 μl/min, using a CMA100 microinfusion pump (CMA 100, Carnegie Medicin, 
Stockholm, Sweden). 
The collection of dialysate samples commenced 300 min after the onset of perfusion to 
achieve stable dialysis glutamate levels (Ferraro et al, 2012) and perfusates were 
collected every 20 minutes thereafter. Following the collection of three stable basal values, 
PCP (2.5 mg/kg) or saline were administered i.p. and other six perfusate samples were 
then collected (total sample collection time: 180 minutes). 
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Following each experiment, the brain was removed from the skull, and the position of the 
dialysis probe was verified using 30 µm-thick coronal cryostat sections. Only those animals 
in which the probe was correctly located were included in this study. 
Glutamate and GABA analysis 
Glutamate and GABA levels in the dialysate were measured by HPLC coupled to 
fluorimetric detection. Briefly, 20 μl samples were pipetted into glass microvials and placed 
in a temperature-controlled (4°C) Triathlon autosampler (Spark Holland, Emmen, The 
Netherlands). 30 μl of o-phthaldialdehyde/mercaptoethanol reagent were added to each 
sample, and 30 μl of the mixture were injected onto a Chromsep analytical column (3 mm 
inner diameter, 10 cm length; Chrompack, Middelburg, The Netherlands). The column was 
eluted at a flow rate of 0.48 ml/minute (Beckman125 pump; Beckman Instruments, 
Fullerton, CA, USA) with a mobile phase containing 0.1 M sodium acetate, 10% methanol 
and 2.2% tetrahydrofuran (pH 6.5). Glutamate and GABA were detected by means of a 
Jasco fluorescence spectrophotometer FP-2020 Plus (Jasco, Tokyo, Japan). The retention 
times of glutamate and GABA were ~3.5 minutes and ~ 15.0 minutes, respectively.  
Data management and statistical analysis 
Basal glutamate and GABA levels are expressed in µM and nM, respectively, and were not 
adjusted for the recovery from the microdialysis probe. Results from individual time points 
are reported as percentages of the mean ± SEM of the three baseline samples collected 
before treatment. Statistical analysis was carried out by analysis of variance (ANOVA), 
followed by the Newman-Keuls test for multiple comparisons. 
In vivo delivery of GAD67 siRNA 
Female Sprague Dawley rats aged 75 PND were anesthetized with chloral hydrate 400 
mg/kg, i.p. (Sigma Aldrich, Italy) and placed in a stereotaxic instrument. 
The target sequence used for GAD67 (Abnova, Walnut, CA) was 
GUAACUGCACACAtggtttcc (sense) and aaaccaUGUGUGCAGUUACCA (antisense). Two 
separate groups of animals were either subjected to sham-operation or injected with the 
Silencer Negative Control, scramble siRNA (Abnova, Walnut, CA), as a negative control. 
GAD67 siRNA was suspended at a final concentration of 20 µg/µl in sterile RNAse free 
water containing 3% MaxSuppressor In vivo RNA-LANCEr II (Bioo Scientific Corporation, 
Austin, TX) and 10% sterile RNAse-free 10x PBS. 
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1.5 µl of the obtained solution were bilaterally injected into the PFC using the following 
coordinates: anterior, 2.70 mm; lateral, 1 mm; depth: -3 mm according to the atlas of 
Paxinos & Watson (1986). Injections were made with a Hamilton syringe at a rate of 0.5 
µl/min using a motorized injector. Following surgery, rats were given an injection of 
amoxicilline (20 mg/kg, i.p., Sigma Aldrich, Italy) and then allowed to recover.  
To investigate the efficacy of siRNA for silencing GAD67 expression, 
immunohistochemistry was performed 3 days after the surgery. 
Data were expressed as mean ± SEM and analyzed by one-way or two-way ANOVA, 
followed by Bonferroni’s post-hoc test. The level of statistical significance was set at 
p<0.05. 
Statistical analysis 
Behavioral and biochemical data were expressed as mean ± SEM and analyzed by 
unpaired Student’s t test and by one-way or two-way ANOVA, followed by Bonferroni’s 
post-hoc test, when appropriate. The level of statistical significance was set at p<0.05. 
2) Methods in Study n.2 
Animals and Isolation rearing procedure 
At weaning (PND 21), male Lister Hooded rats (Harlan, Italy) were randomly housed in 
groups of 4 (grouped) or alone (isolated). All animals were housed in the same room and 
had visual, auditory and olfactory contact with animals caged nearby, on a 12 hour light-
dark cycle (lights on 08:00h) and in a temperature (24 ± 2°C) and humidity controlled 
environment (50±10%). All animals had free access to food and water. The isolated 
animals were left undisturbed in their cages and received the minimal handling associated 
with husbandry (cage and bedding changed weekly). 
All experiments were carried out during the light phase and performed in accordance with 
the guidelines released by the Italian Ministry of Health (D.L.116/92) and (D.L.111/94-B), 
and the European Community directives regulating animal research (86/609/EEC). All 
efforts were made to minimize the number of animals used and their suffering. 
Drug administration 
AM251 (Tocris, Italy) was dissolved in DMSO, Tween-80 and saline (1:1:8). The drug was 
acutely or chronically administered at 0.5mg/kg (with the injection volume of 0.5ml/kg), i.p. 
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For acute treatment each animal received a single injection 80 minutes before the test 
session, whereas for chronic administration AM251 was given daily for 3 weeks and 
animals underwent a series of behavioral tests 24 hours, 72 hours and 10 days after the 
last AM251 (or vehicle) administration. The different behavioral tests were performed on 
separate groups of animals, according to the timeline shown in Fig. 7. 
Behavioral tests 
Spontaneous Locomotor Activity 
Rats were placed in a computer-controlled infra-red activity monitor arena. The arena 
consisted of a clear acrylic box, 43×43×32 cm (Ugo Basile, Varese, Italy) placed in a 
sound-attenuating room. The cage was fitted with two parallel infrared beams, located 2 
and 6 cm from the floor and cumulative horizontal and vertical movement counts were 
recorded for 1 hour. 
Novel object recognition (NOR) test 
The experimental apparatus used for the object recognition test was an open-field box 
(cm60x60x60cm) made of plexiglass, placed in a dimly illuminated room. Animals 
performed each test individually. 10 minutes habituation session preceded the 
experimental trials. The experiment was performed and analyzed as previously described 
in Viganò et al., (2009). Briefly, after the habituation each animal was placed in the arena 
and allowed to explore two identical previously unseen objects for 10 minutes 
(familiarization phase). After an inter-trial interval of 1 hour one of the two familiar objects 
were replaced by a novel previously unseen object and rats were returned to the arena for 
the 3 minutes test phase. During the test phase the time spent exploring the familiar 
objects (Ef) and the new object (En) was videotaped and recorded separately by two 
observers blind to the treatment groups and .the discrimination index was calculated as 
follow: [(En-Ef)/(En+Ef)]*100. 
Social interaction test 
The test was carried out in a room illuminated with a dim overhead light. On the day of 
testing, each animal was habituated for 10 minutes in the test arena (cm60x60x60cm) 
made of plexiglass. During the test session, each animal was allowed to freely exploring 
an unfamiliar congener in the arena for 10 minutes. The arena was cleaned with 0.1% 
acetic acid and dried after each trial. Social behaviors were defined as sniffing, following, 
grooming, mounting and nosing. Aggressive behaviors were defined as attacking, biting, 
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tail rattling and aggressive grooming. The whole testing phase was videotaped, analyzed 
by two observers blind to the treatment groups and we reported the time spent in social 
behaviors and the number of aggressive behaviors. 
Prepulse inhibition of startle reflex apparatus  
The startle reflex system is composed by 4 standard cages each placed into a sound-
attenuated and ventilated chamber (Med Associated, USA). Plexiglas cylinders (diameter 
9 cm),closed by two doors to restrict the animals, were mounted on a piezoelectric 
accelerometer platform connected to an analogue-digital converter. Background noise and 
acoustic bursts were conveyed through two speakers placed in proximity to the startle 
cage so as to produce a variation in sound intensity within 1 dB. On test day, each rat was 
placed in the experimental cage for a 5 min acclimatization period with a 70 dB white noise 
background; this was continued for the remainder of the session. Animals were then tested 
on 3 consecutive trial blocks. The first and the third blocks consisted of 5 pulse-alone trials 
of 40 ms at 115 dB, while the second block (test block) was a pseudorandom sequence of 
50 trials including 12 pulse-alone trials, 30 pulse trials preceded by 74, 78 or 82 dB 
prepulses (10 for each level of prepulse loudness), and 8 no-stimulus trials (where the only 
background noise was delivered). The percent (%) PPI was calculated based only on the 
values relative to the second block, and using the following formula: 100-[(mean startle 
amplitude for prepulse+pulse trials/mean startle amplitude for pulse-alone trials)×100]. 
Biochemical assays 
Autoradiographic-binding assays 
For assessment of long-term effects of isolation rearing and AM251 treatment on CB1 
receptor function, biochemical analysis were performed on separate groups of animals not 
tested for behavior. Rats were decapitated and brains were rapidly removed, frozen in 
liquid nitrogen and stored at -80°C until processing. 
Coronal sections (20μm thick) were cut on a cryostat and mounted on gelatin-coated 
slides. The sections were stored at –80°C until processing. 
[3H]CP-55,940 receptor autoradiographic binding 
The [3H]CP-55,940 receptor autoradiographic binding was performed as previously 
described (Rubino et al., 2000; Viganò et al., 2009). 
CP-55,940-stimulated [35S]GTPγS binding in autoradiography 
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This was determined as previously described (Rubino et al., 2000; Viganò et al., 2009). 
[3H]SCH23390 and [3H]Raclopride receptor autoradiographic binding 
The experiments were performed as described previously (Léna et al., 2004). For the D1 
receptor binding, sections were prewashed for 20 min in 50 mM Tris–HCl buffer, pH 7.4, 
containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, and 1 mM MgCl2 at room temperature. 
The sections were then incubated in the same buffer at room temperature in the presence 
of 4 nM [3H]SCH23390 (PerkinElmer Life Sciences, Milan, Italy) for 90 min to label the D1 
receptors. For D2 receptors detection, slides were pre-incubated in the same Tris buffer as 
the D1 receptors. Incubation was carried out in the presence of 4 nM [3H]raclopride for 60 
min. Both incubations were terminated by rapid rinses in icecold 50 mM Tris–HCl buffer pH 
7.4, followed by a dip into ice-cold distilled water, before they were rapidly dried in a 
stream of cold air. Sections were exposed to Kodak Biomax MR films (PerkinElmer Life 
Sciences, Milan, Italy) and developed after 6 (D1 receptor) or 10 (D2 receptor) weeks. 
[3H]MK-801 receptor autoradiographic binding 
The experiment was performed as previously described by Newell et al. (2007). Sections 
were incubated at room temperature for 2.5 h in 30 mM HEPES buffer containing 20 nM 
[3H]MK801 (Perkin Elmer Life Sciences, Milan, Italy) and exposed to Kodak Biomax MR 
films for 5 weeks. 
Image analysis 
The intensity of the autoradiographic films was assessed as previously reported in Rubino 
et al. (2000). Data were expressed as fmol/mg of tissue. 
Endocannabinoid levels 
Separate animals not subjected to PPI procedure were used for the dissection of  PFC, 
CPu, NAc and Hippo after 5 weeks of isolation or social rearing and 24 hours after the last 
AM251 (or vehicle) injection. The collected areas were immediately frozen in liquid 
nitrogen and stored at -80°C. 
Extraction and quantification of endocannabinoids 
Frozen tissue samples were homogenized in chloroform/methanol/TRIS-HCl 50 mM pH 
7.4 (2:1:1, v/v) containing 10 pmol of [2H]8-AEA, [2H]4-PEA and [2H]4-OEA, and 50 pmol of 
[2H]5-2-AG as internal deuterated standards (purchased from Cayman Chemicals, Ann 
Arbor, MI). The extract was purified by means of silica gel mini-columns as described in 
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Bisogno et al. (1997), and the eluted fraction containing AEA and 2-AG analysed by 
means of liquid chromatography-atmospheric pressure-mass spectrometry (LC-APCI-MS) 
conducted as described previously (Marsicano et al., 2002). Analyses were carried out in 
the selected ion-monitoring mode using m/z values of 356 and 348 (molecular ions +1 for 
deuterated and undeuterated AEA), 304 and 300 (molecular ions +1 for deuterated and 
undeuterated PEA), 330 and 326 (molecular ions +1 for deuterated and undeuterated 
OEA), and 384.35 and 379.35 (molecular ions +1 for deuterated and undeuterated 2-AG). 
AEA, OEA, PEA and 2-AG concentrations were calculated by isotope dilution and are 
expressed as pmol per g or mg of wet tissue weight. The concentrations of 2-AG were 
obtained by adding up to the amounts of the 2-isomer also those of the 1(3)-isomer, which 
mostly originates from the isomerization of the former during work-up. 
Statistical analysis 
Behavioral and biochemical results were analyzed by unpaired Student’s t-test or a two-
way ANOVA with housing conditions and drug treatment as independent variables, 
followed up by Bonferroni’s post hoc test. PPI data were analyzed with unpaired Student’s 
t-test or two-factor analysis of variance (ANOVA) with rearing condition or drug treatment 
as between-subjects factor and trial type (prepulse intensity) as repeated measure (within-
subjects factor) followed by Bonferroni’s post hoc test. All data were expressed as mean ± 
SEM. The level of statistical significance was set at p<0.05. 
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1) Results of Study n.1 
Behavior 
Adolescent THC treatment leads to the development of a psychotic-like phenotype 
in adult female rats 
Negative-like symptoms and cognitive signs 
Figure 2 shows the behavioral phenotype of adult rats treated with THC during 
adolescence in comparison with the behavioral effect observed in animals sub-chronically 
administered with PCP, a validated animal model of schizophrenia (Fig. 1A and B). 
Panel A represents the effect of adolescent THC administration and sub-chronic PCP 
treatment in the NOR test. As expected, sub-chronic PCP administration induced a 
significant cognitive impairment in the classic version of the NOR test, as stated by the 
significant reduction in the discrimination index by about 100% compared to controls. A 
greater cognitive deficit was observed in the spatial version of the test, the discrimination 
index being reduced by about 190%. Interestingly, adolescent THC treatment triggered the 
development of a cognitive impairment in adulthood similar to that induced by sub-chronic 
PCP administration both in the classic and in the spatial variant of the NOR test, the 
discrimination index being significantly reduced by about 100% and 200% respectively. 
The time spent exploring the two identical objects during the familiarization phase and the 
locomotor activity was not altered in any of the groups analyzed (data not shown). 
Panel B represents the effect of adolescent THC administration and sub-chronic PCP 
treatment in the social interaction test. As expected, sub-chronic PCP administration 
significantly reduced the time spent in active social behaviors in the 10-minute test session 
by about 50% when compared to vehicle-treated rats. Adolescent THC exposure induced 
a similar reduction in social behaviors (40%). Aggressive behaviors were not observed in 
any of the groups under investigation. 
Panel C shows the effect of adolescent THC administration and sub-chronic PCP 
treatment in the FST. The sub-chronic PCP protocol induced a significant increase by 
about 80% in the time spent in immobility during the 15-minute test session. A significant 
increase in the immobility time by about 80% was also observed in adult animals that 
underwent adolescent THC treatment. In both experimental groups the increase in the 
immobility time was paralleled by a significant reduction of the time spent in swimming 
activity. 
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Sensitization to PCP-induced hyperlocomotion 
Another endophenotype of schizophrenia is the presence of hypersensitivity to acute PCP 
administration (Lazar et al, 2011). To test whether adolescent THC treatment sensitizes 
the behavioral response to acute PCP on measures of locomotor activity and stereotyped 
behaviors, adult rats exposed to THC during adolescence were injected with PCP 2.5 
mg/kg according to the treatment schedule reported in Figure 1C. Rat behavior was then 
monitored for 50 minutes in the activity cage. 
Figure 2, panel D, represents locomotor activation and stereotyped behaviors in response 
to acute PCP administration in adult rats exposed to THC during adolescence. No 
differences were observed in the basal locomotor activity between vehicle- and THC-
treated rats during the whole test session. The dose of PCP we used (2.5 mg/kg) did not 
induced locomotor activation in vehicle-treated animals but significantly increased 
locomotion in THC-treated rats. In particular, no locomotor activation was observed during 
the first and the last 10-minute trials, but two-way ANOVA revealed significant THC, PCP 
and THCxPCP main effects during the 20-, 30- and 40-minute trials (20-minutes: THC: F1-
20=34.62; p<0.0001; PCP: F1-20=11.78; p=0.0050; THCxPCP interaction: F1-20=26.39; 
p=0.0002; 30-minutes: THC: F1-20=22.32; p=0.0005; PCP: F1-20=9.424; p=0.0097; 
THCxPCP interaction: F1-20=17.25; p=0.0013; 40-minutes: THC: F1-20=12.67; p=0.0039; 
PCP: F1-20=0.6995; p=0.4193; THCxPCP interaction: F1-20=7.584; p=0.0175). In fact, THC-
treated rats showed an enhanced locomotor activation in response to acute PCP by about 
320%, 370% and 200% respectively compared to the other experimental groups. 
Statistical analysis also revealed significant THC, PCP and THCxPCP main effects on 
stereotyped behaviors during the whole 50-minute test session (10-minutes: THC: F1-
20=5.428; p=0.0381; PCP: F1-20=5.428; p=0.0381; THCxPCP interaction: F1-20=5.428; 
p=0.0381 20-minutes: THC: F1-20=23.17; p=0.0004; PCP: F1-20=210.2; p<0.0001; 
THCxPCP interaction: F1-20=23.17; p=0.0004; 30-minutes: THC: F1-20=19.70; p=0.0008; 
PCP: F1-20=240.5; p<0.0001; THCxPCP interaction: F1-20=19.70; p=0.0008; 40-minutes: 
THC: F1-20=21.48; p=0.0006; PCP: F1-20=322.1; p<0.0001; THCxPCP interaction: F1-
20=21.48; p=0.0006; 50-minutes: THC: F1-20=8.040; p=0.0150; PCP: F1-20=60.89; 
p<0.0001; THCxPCP interaction: F1-20=8.040; p=0.0150). In fact, stereotyped behaviors 
were observed in vehicle-treated animals following acute PCP injection and this effect was 
significantly enhanced in THC-treated rats, PCP-induced stereotyped behaviors being 
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significantly higher in THC-treated rats than in vehicle-treated rats during the whole 50-
minute test session. 
Biochemical analyses 
Role of PFC GABAergic signaling in the negative-like symptoms and cognitive signs 
induced by adolescent THC treatment 
Research to date suggests that cortical GABAergic deficits contribute to both the 
pathophysiology and symptomatology of schizophrenia (Nakazawa et al, 2012). Since 
important interactions between the endocannabinoid and the GABAergic systems have 
been largely demonstrated (Lopez-Moreno et al, 2008), we checked whether adolescent 
THC administration could lead to long-term alterations in the GABAergic transmission in 
terms of GAD67, parvalbumin (PV), VGAT and cholecystokinin (CCK) protein levels as 
well as basal GABA levels in the PFC of adult rats.  
Figure 3A represents the impact of adolescent THC exposure on GAD67, PV, VGAT and 
CCK protein levels in the PFC of adult rats. 
No changes were observed in PV, VGAT and CCK levels in the PFC of adult animals 
administered with THC during adolescence. In contrast, adolescent THC administration 
significantly reduced the enzyme responsible for most GABA synthesis in adulthood, 
GAD67 protein levels being significantly reduced in the PFC by about 45% compared to 
vehicle-treated rats. 
As shown in figure 3B, the reduction of GAD67 expression was not evident in the middle 
and late adolescence (PND 46 and 60), but only developed in adulthood (PND 75) (two 
way ANOVA for age: F2-37=59.23; p<0.0001; agexTHC interaction: F2-37=13.31; p<0.0001), 
suggesting a possible reduction in GABA synthesis. 
Figure 3C shows that extracellular GABA levels in the PFC of THC-treated animals were 
significantly lower than those measured in vehicle-treated rats.  
Since GAD67 is expressed either in PV- as well as in CCK-containing interneurons, double 
immunofluorescence for GAD67, PV and CCK proteins was performed to check in which 
neuronal subpopulation was present the reduction in GAD67 protein expression. 
Immunocolocalization of GAD67 and PV and of GAD67 and CCK proteins in the PFC is 
represented in figure 4A and B, respectively. GAD67 was reduced by about 60% both in 
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PV- and CCK-containing interneurons in the PFC of THC-treated rats compared to vehicle-
treated animals. 
To assess whether the alterations in GABAergic transmission could be extended to other 
brain areas relevant to schizophrenia, the same biochemical analyses were performed in 
the hippocampus of adult animals that underwent adolescent THC administration. No 
changes were observed in GAD67, PV, VGAT and CCK levels in the hippocampus of adult 
animals chronically administered with THC during adolescence (data not shown). 
Finally, to understand the functional meaning of the specific reduction of GAD67 levels in 
the PFC and the possible relationship between this molecular alteration and the behavioral 
phenotype induced by adolescent THC treatment, we knocked down GAD67 expression 
through a siRNA-mediated gene silencing approach. GAD67 siRNA was bilaterally injected 
in the PFC of adult naïve animals and their behavior was investigated in the NOR test, 
social interaction test, FST and on the locomotor response to acute PCP administration. 
Silencing efficacy of GAD67 siRNA was analyzed by immunohistochemistry. As reported 
in figure 5A, 72 hours after an acute bilateral injection of GAD67 siRNA, GAD67 
expression was significantly reduced by about 70% compared with controls. 
Figure 5 (B-E) shows the effect of GAD67 siRNA delivery in the PFC on the rat behavioral 
responses as measured in the NOR test (fig. 5B), social interaction test (fig. 5C), FST (fig. 
5D) and on PCP-induced locomotor activation (fig. 5E). Animals were tested 72 hours after 
the injection. Sham-operation and scramble siRNA injection did not alter the behavioral 
responses in all the test performed. Silencing GAD67 expression in the PFC by in vivo 
siRNA injection did not induce any behavioral alteration in the NOR (fig. 5B) and in the 
social interaction test (fig. 5C) and did not affect the locomotor response induced by acute 
PCP injection (fig. 5E). In fact, no changes in locomotor activity were observed following 
PCP administration in any of the groups analyzed. Statistical analysis only revealed a PCP 
effect on stereotyped behaviors during the whole test session (10-minutes: F1-24=142.3; 
p<0.0001; 20-minutes: F1-24=252.1; p<0.0001; 30-minutes: F1-24=287.9; p<0.0001; 40-
minutes: F1-24=105.4; p<0.0001; 50-minutes: F1-24=85.39; p<0.0001). 
In contrast, lower GAD67 expression in the PFC resulted in a significant increase in the 
time spent in immobility (80%) in the FST compared with controls (fig. 5D). This increase 
in immobility was paralleled by a significant reduction in climbing and swimming activities. 
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Alterations in neural activation and glutamate release underlying THC-induced 
sensitization to acute PCP 
To assess whether a different neuronal activation in response to acute PCP could underlie 
the increased behavioral response observed in THC-treated rats, c-Fos immunoreactivity 
was monitored in the PFC and CPu of THC- and vehicle-exposed animals, two brain 
regions involved in the development of behavioral sensitization (Vanderschuren and 
Kalivas, 2000)  
Figure 6A represents c-Fos immunoreactivity in response to acute PCP in the PFC and 
CPu of THC-exposed rats and vehicle-treated animals. 
In the PFC, statistical analysis revealed significant THC, PCP and THCxPCP main effects 
(THC: F1-12=54.36; p<0.0001; PCP: F1-12=55.00; p<0.0001; THCxPCP interaction: F1-
12=5.377; p=0.0484). Vehicle administration did not alter c-Fos expression in THC pre-
treated rats. The low dose of PCP we used (2.5 mg/kg) did not induce by itself neuronal 
activation in this brain area but its administration in THC-treated animals caused a 
significant increase in c-Fos immunoreactivity by about 35% compared to vehicle-treated 
animals. 
In the CPu, statistical analysis revealed significant THC, PCP and THCxPCP main effects 
(THC: F1-12=54.36; p<0.0001; PCP: F1-12=55.00; p<0.0001; THCxPCP interaction: F1-
12=4.377; p=0.0494). In fact, both THC and PCP by themselves significantly increased c-
Fos expression by about 53%, and a further increase in c-Fos immunoreactivity was 
evident when PCP was administered in THC-treated rats (+60% compared to THC and 
PCP alone). 
Figure 6B represents the effects of acute PCP injection (2.5 mg/kg) on PFC extracellular 
glutamate and GABA levels in vehicle- and THC-treated rats. 
A slight increase in PFC extracellular glutamate levels was observed after PCP injection in 
control animals. In contrast, PCP significantly increased extracellular glutamate levels in 
the PFC of THC-treated rats. This effect reached statistical significance 40-minutes after 
the drug injection and was associated with a slight, not significant, reduction of 
extracellular GABA levels. No significant changes in PFC extracellular GABA levels were 
observed after PCP injection in control animals. 
Similarly, PCP induced a significant increase of extracellular glutamate levels in the dorsal 
striatum of THC-treated rats, but not in control rats. No changes in striatal extracellular 
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GABA levels were found after PCP administration in both groups under investigation (Fig. 
6C). 
2) Results of Study n.2 
Behavioral assessment of isolation-rearing protocol 
Figure 8 shows the behavioral scene after 5 weeks of isolation rearing. 
Isolation-reared rats were significantly more active in the novel environment than group-
housed rats (t=8.820, p<0.0001) without any alteration in rearing activity between the two 
groups (t=1.876, p=0.0832) (Fig. 8a). Moreover, the isolation-rearing protocol caused an 
impairment of cognitive functions as demonstrated by a significant reduction in the 
discrimination index during the test phase of the NOR test (t=10.25, p<0.0001) compared 
to group-reared controls. In both groups there was no difference in the time spent 
exploring the two identical objects during the familiarization phase (data not shown), but 
isolated animals failed to discriminate between the new and familiar object in the test 
phase (Fig. 8b). The locomotor activity was not altered both in grouped and isolated rats 
(data not shown). In the social interaction test, no differences were found in the time spent 
in active behaviors between isolation- and group-reared animals (t=0.1969, p=0.8504) but 
isolation rearing caused a significant increase in aggressive behaviors compared to group-
reared controls (t=32.75, p<0.0001) (Fig. 8c). Figure 8d represents the effect of rearing 
condition on % pre-pulse inhibition startle magnitude (% PPI). Both housing condition and 
AM251 treatment did not alter the magnitude of the startle response (data not shown). At a 
pre-pulse intensity of 74 dB, isolation-reared rats showed a significant lower %PPI than 
group-housed controls PPI (n=19) (t=6.756; p<0.0001). A significant disruption in the PPI 
response, although less intense, was still evident in isolated rats at a pre-pulse intensity of 
78 dB (t=3.466; p=0.0026) and 82 dB (t=2.491; p=0.0221) compared with social controls. 
Effect of the isolation-rearing protocol on CB1R functionality 
After 5 weeks of isolation rearing, we investigated the effects of housing condition on 
CB1R density and functionality. 
Figure 9a shows the effects of isolation rearing on CB1R density. Isolation rearing had no 
effect on CB1R density in all the cerebral regions analyzed. 
We found significant changes in CB1R functionality as shown by the GTPγS binding assay 
(Fig. 9b). Particularly, the isolation-rearing protocol induced a significant reduction in CB1R 
functionality in the PFC (t=2.093, p=0.0481), NAc (t=3.572, p=0.0017), caudate putamen 
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(CPu) (t=3.507, p=0.0020), hippocampus (Hippo) (t=2.546, p=0.0216) and ventral 
tegmental area (VTA) (t=3.438, p=0.0044). 
Effect of the isolation-rearing protocol on endocannabinoid levels 
Figure 10 shows the effect of 5 weeks of social isolation on endocannabinoid levels in the 
PFC, NAc, CPu and Hippo. 
In the PFC, social isolation induced a significant reduction in 2-AG levels by about 52% 
(t=2.525; p=0.0450) compared with group-reared controls. Moreover, a significant increase 
in PEA content (+59%) was evident in isolated rats (t=3.827; p=0.0187). No changes were 
found in AEA and OEA levels following 5 weeks of isolation rearing (AEA: t=0.3344; 
p=0.7494; OEA: t=0.9077; p=0.3990). 
Similarly, in the NAc, a significant reduction in 2-AG content (-23%) was present following 
the isolation rearing procedure (t=2.744; p=0.0336). No changes in AEA, PEA and OEA 
levels were observed (AEA: t=0.4032; p=0.7035; PEA: t=0.1621; p=0.8765; OEA: t=1.183; 
p=0.2814). 
Finally, isolated animals showed a significant increase in 2-AG levels in both the CPu 
(t=3.051; p=0.0284) and hippocampus (t=2.957; p=0.0316) by about 170% and 67% 
respectively. AEA, PEA and OEA levels did not differ from controls in these two brain 
areas (CPu: AEA: t=0.3681; p=0.7254; PEA: t=0.2863; p=0.7843; OEA: t=1.091; 
p=0.3250. Hippo: AEA: t=1.106; p=0.3112; PEA: t=0.2914; p=0.7805; OEA: t=1.166; 
p=0.2877). 
Effect of the isolation-rearing protocol on dopamine D1 and D2 receptor densities 
The effect of social isolation on dopamine D1 and D2 receptor densities in the PFC, CPu 
and NAc is illustrated in Figure 11A. 
Isolated animals showed a significant reduction in D1 receptor density in the PFC by about 
71% compared with group-reared controls (t= 6.680; p<0.0001). No significant changes in 
[3H]-SCH23390 binding were observed in the CPu (t=1.651; p=0.1130) and NAc (t=1.480; 
p=0.1529) following the isolation procedure. In contrast, D2 receptor density was 
significantly increased in the PFC of isolated rats by about 82% (t=5.181; p=0.0001). 
Isolation rearing did not alter [3H]-raclopride binding in the CPu (t=2.045; p=0.0601) and 
NAc (t=0.3168; p=0.7560). 
Effect of the isolation-rearing protocol on glutamate NMDA receptor density 
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Figure 11B shows the effect of isolation rearing on glutamate NMDA receptor binding in 
the PFC, CPu, NAc, Hippo, amygdala (Amy) and thalamus (Thal). 
A significant decrease in NMDA receptor density was present in the CPu following 5 
weeks of isolation rearing (t=2.766; p=0.0113). Isolated animals also displayed a 
significant increase in [3H]-MK-801 binding in the NAc compared with group-housed 
controls (t=2.566; p=0.0184). No changes were observed in the PFC (t=1.819; p=0.0825), 
Hippo (t=0.5691; p=0.5751), Amy (t=0.7774; p=0.4452) and Thal (t=0.4034; p=0.6905) 
following isolation rearing. 
Effect of acute AM251 administration on cognitive impairment and aggressive 
behavior induced by isolation rearing protocol 
Figure 12 shows the effects of acute AM251 administration on isolation-induced cognitive 
deficit and aggressiveness. 
In the novel object recognition test, acute AM251 treatment did not alter the exploration 
time in the familiarization phase both in grouped and isolated rats (data not shown) and 
failed to improve the recognition memory disrupted by social isolation rearing (two-way 
ANOVA for housing: F1,12=75.24, p<0.0001; two-way ANOVA for drug: F1,12=0.0001214, 
p=0.9914; no interactions) (Fig.12a). Moreover, acute AM251 alone did not affect the 
discrimination index in socially reared rats and there were no differences in the locomotor 
activity between all the groups considered (data not shown). 
In the social interaction test acute AM251 did not significantly reduce the number of 
aggressive events in isolation reared rats (two-way ANOVA for housing: F1,12=148.6, 
p=0.9914; two-way ANOVA for drug: F1,12=2.673, p=0.1280; no interactions). Neither 
housing conditions or AM251 treatment affected the time spent in social behaviors during 
the social interaction test (two-way ANOVA for housing: F1,12=0.3768, p=0.5508; two-way 
ANOVA for drug: F1,12=1.844, p=0.1995; no interactions) (Fig.12B). 
Behavioral characterization after chronic AM251 (or vehicle) treatment in isolated 
and group-housed rats 
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Figure 13 shows the effects of chronic AM251 administration on isolation-induced 
cognitive impairment. 
The discrimination index impaired in isolation-reared rats was restored after 3 weeks of 
chronic AM251 treatment (housing: F1,12=6.834, p=0.0226; drug: F1,12=4.755, p=0.0498; 
drug x housing interaction : F1,12=19.43, p=0.0023) and the recovery of this parameter was 
still evident at 72 hours (housing: F1,12=5.482, p=0.0373; drug: F1,12=12.27, p=0.0044; no 
interaction) and 10 days after the last AM251 administration (housing: F1,12=10.48, 
p=0.0071; drug: F1,12=6.403, p=0.0264; drug x housing interaction : F1,12=10.39, 
p=0.0073). Neither housing conditions nor AM251 treatment altered the time spent 
exploring the two identical objects during the familiarization phase (data not shown) and 
AM251 alone did not affect the recognition memory in socially reared rats. The locomotor 
activity was not altered in any of the groups analyzed (data not shown). 
Figure 14 shows the effects of chronic AM251 treatment on the aggressive behaviors in 
the social interaction test. 
We observed a reduction in the number of aggressive behaviors in isolation-reared rats 72 
hours and 10 days after the last AM251 administration compared to what was observed in 
the social interaction test performed 24 h after the last injection. However, the aggressive 
behaviors in isolation-reared rats were still significantly increased compared to group-
reared controls at both time-points. Isolation-reared rats chronically administered with 
AM251 showed a significant reduction in the number of aggressive events in the social 
interaction test performed 24 hours after discontinuing treatment (drug: F1,12=13.71, 
p=0.0030; drug x housing interaction : F1,12=13.71, p=0.0030) and this recovery was still 
evident at 72 hours (drug: F1,12=11.37, p=0.0056; drug x housing interaction: F1,12=11.37, 
p=0.0056) and 10 days (drug: F1,12=6.716, p=0.0236; drug x housing interaction : 
F1,12=6.716, p=0.0236) after the last AM251 administration. Chronic AM251 per se did not 
alter the time spent in social behaviors. 
Figure 15 shows the effect of chronic AM251 (or vehicle) treatment on PPI response in 
isolation- and group-reared rats. 
Two-way ANOVA revealed a significant effect of rearing conditions on PPI response at 74 
and 78 dB intensities (74 dB: F1-15=13.41; p=0.0023; 78 dB: F1-15=16.15; p=0.0011), PPI 
disruption being still evident in isolation-reared animals compared to group-housed 
controls following vehicle treatment. The effect of rearing conditions on PPI response was 
not present at 82 dB intensities (F1-15=2.471; p=0.1368). 
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AM251 treatment did not affect PPI response in control animals at any of the dB intensities 
tested (74 dB: F1-15=2.263; p=0.1533; 78 dB: F1-15=0.4114; p=0.5309; 82 dB: F1-
15=0.02212; p=0.8837). 
In contrast, AM251 administration completely counteracted PPI disruption in isolated rats 
at 74 as well as 78 dB intensities (74 dB: F1-15=5.750; p=0.0299; 78 dB: F1-15=4.562; 
p=0.0496). 
Neurochemical characterization after chronic AM251 (or vehicle) treatment in 
isolated and group-housed rats 
Effect of AM251 chronic treatment on CB1 receptor functionality 
After 3 weeks of chronic AM251 (or vehicle) treatment we found no alterations in the CB1 
receptor density, both in group housed and isolation reared rats, in all the brain regions 
analyzed (Figure 16a). 
Figure 16b represents the results of CP-55,940-stimulated GTPγS autoradiographic-
binding assay performed 24 hours after the last chronic  AM251 (or vehicle) administration. 
AM251 had no effect on CB1 receptor functionality in group housed controls but 
counteracted the alterations observed in rats reared in isolation in the PFC, NAc, Hippo 
and VTA. After 3 weeks of chronic vehicle treatment, isolation reared rats still showed a 
significant reduction in the CB1 receptor functionality in the PFC, NAc, Hippo and VTA 
compared to group housed controls (PFC: two-way ANOVA for housing: F1,28=6.610, 
p=0.0157; NAc: two-way ANOVA for housing: F1,28=7.083, p=0.0127; Hippo: two-way 
ANOVA for housing: F1,28=8.549, p=0.0068; VTA: two-way ANOVA for housing: 
F1,28=8.549, p=0.0068), indicating that these alterations were not influenced by daily 
handling. The reduction reported in isolation reared rats were counteracted by AM251 
chronic administration (PFC: two-way ANOVA for drug x housing interaction: F1,28=8.881, 
p=0.0059; NAc: two-way ANOVA for drug x housing interaction: F1,28=5.848, p=0.0223; 
Hippo: two-way ANOVA for drug x housing interaction: F1,28=8.410, p=0.0072). 
Endocannabinoid levels 
Figure 17 represents endocannabinoid levels following chronic AM251 (or vehicle) 
administration in respect to housing conditions. 
Effect of chronic handling on endocannabinoid content 
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Endocannabinoid levels appeared to be particularly influenced by chronic handling due to 
vehicle/drug administration in isolated animals. Thus we first checked whether handling 
procedure per se further modify the isolation rearing-induced alteration in endocannabinoid 
levels. 
In the PFC, a significant effect of handling was evident on OEA content in isolated rats (F1-
12=9.588; p=0.0092), OEA levels being reduced in both vehicle- and AM251-treated 
animals. AM251 administration did not affect OEA content in group housed controls (F1-
12=0.08697; p=0.7731). Moreover, in the same brain regions, handling counteracted 
isolation-induced increase in PEA levels (F1-12=4.83; p=0.036). 
Similarly, in the NAc, a significant handling effect was found on OEA levels (F1-12=12.38; 
p=0.0042), with reduction of OEA content both in vehicle and in AM251 treated rats. 
Finally, in the CPu and hippocampus, two-way ANOVA revealed a significant main effect 
of handling on endocannabinoid content (F1-12=6.57; p=0.017). Specifically, chronic 
handling completely counteracted the isolation-induced increase in 2-AG in the CPu, but 
caused an increase in AEA levels in .the hippocampus 
In summary, 3 weeks of handling induced in the PFC and NAc a significant reduction in 
OEA levels, resistant to AM251 treatment, completely reversed in the CPu the 5 weeks 
isolation-induced increase in 2-AG and induced an increase in AEA levels in the 
hippocampus. In contrast, handling did not affect the significant alterations in 2-AG levels 
measured in the PFC, NAc and hippocampus after 5 weeks of isolation. 
Effect of AM251 administration on endocannabinoid content 
In the PFC, social isolation procedure significantly reduced 2-AG levels in vehicle treated 
rats (F1-12=6.637; p=0.0258). Interestingly, AM251 administration did not alter 2-AG levels 
in control animals (F1-12=1.472; p=0.2504) but completely restored 2-AG levels in isolated 
rats (F1-12=10.72; p=0.0074). 
Neither isolation rearing nor AM251 treatment altered AEA and PEA levels in this brain 
area (AEA: housing condition: F1-12=1.732; p=0.2120; drug: F1-12=0.00007932; p=0.9930. 
PEA: housing condition: F1-12=0.2793; p=0.6068; drug: F1-12=0.06082; p=0.8094). 
Similarly, in the NAc, two-way ANOVA revealed a significant effect of housing conditions 
on 2-AG content (F1-12=10.23; p=0.0095), its levels being significantly reduced in isolation 
reared rats chronically treated with vehicle. AM251 administration counteracted the 
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isolation-induced reduction of 2-AG (F1-12=5.167; p=0.0463) without affecting 2-AG content 
in control animals (F1-12=3.944; p=0.0751). 
No effect of isolation rearing were observed on AEA and PEA content (AEA: F1-12=0.2595; 
p=0.6205; PEA: F1-12=3.298; p=0.0944) and AM251 treatment did not affect AEA, PEA and 
OEA levels in this brain region (AEA: F1-12=0.6064; p=0.4526; PEA: F1-12=0.2132; 
p=0.6526; OEA: F1-12=1.103; p=0.3143). 
In the Hippo, AEA (F1-12=5.112; p=0.0450) and 2-AG (F1-12=7.271; p=0.0224) levels were 
significantly increased in isolated rats compared to group housed controls, although, as 
mentioned above, the effect on AEA was probably due to handling. Interestingly, AM251 
administration completely reversed the isolation-induced increase in 2-AG (F1-12=7.061; 
p=0.0240) and the handling -induced increase in AEA (F1-12=38.99; p<0.0001), without 
affecting per se their contents in group housed controls (AEA: F1-12=2.438; p=0.1467; 2-
AG: F1-12=4.493; p=0.0601). 
Neither social isolation nor AM251 administration altered PEA (housing condition: F1-
12=0.7320; p=0.4123; Drug: F1-12=0.1241; p=0.7319) and OEA (housing condition: F1-
12=0.7937; p=0.3921; Drug: F1-12=1.530; p=0.2419) levels in this brain area. 
Finally, in the CPu, isolation rearing procedure did not alter AEA, 2-AG, PEA and OEA 
levels (AEA: F1-12=0.5577; p=0.4696; 2-AG: F1-12=0.07726; p=0.7862; PEA: F1-12=0.1744; 
p=0.6836; OEA: F1-12=1.262; p=0.2833). In contrast, two-way ANOVA revealed a 
significant effect for drug treatment on PEA levels (F1-12=10.61; p=0.0069), with AM251 
treatment slightly increasing PEA content in both isolated and group-housed rats. AM251 
administration did not alter AEA (F1-12=0.03262; p=0.8597), 2-AG (F1-12=1.120; p=0.3127) 
and OEA (F1-12=0.3095; p=0.5882) levels in this brain region. 
Effect of AM251 administration on dopamine D1 and D2 receptor densities 
Figure 18a shows the effect of AM251 (or vehicle) administration on dopamine D1 and D2 
receptor densities in isolated and group-reared animals. 
Isolation rearing significantly reduced D1 receptor density in the PFC (F1-12=46.50; 
p<0.0001), the effect being evident both in AM251 and vehicle-treated rats. No effect of 
isolation rearing on [3H]SCH23390 binding was observed in the CPu (F1-12=0.1546; 
p=0.6970) and NAc (F1-12=2.577; p=0.1193). 
AM251 treatment did not affect [3H]SCH23390 binding in the PFC (F1-12=0.04747; 
p=0.8291) and CPu (F1-12=0.7729; p=0.3866). In contrast, two-way ANOVA showed a 
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significant effect of drug treatment in the NAc (F1-12=5.439; p=0.0268), D1 receptor density 
being significantly down-regulated in isolation reared rats (F1-12=8.015; p=0.0083). 
In the PFC, statistical analysis revealed a significant effect of housing conditions (F1-
12=5.360; p=0.0264), drug treatment (F1-12=8.387; p=0.0064) and housing condition x drug 
treatment interaction (F1-12=20.50; p<0.0001) on dopamine D2 receptor density. Isolation 
rearing significantly increased [3H]Raclopride binding in this brain area and AM251 
administration completely antagonized the isolation-induced alteration. 
Neither isolation rearing nor AM251 treatment altered D2 receptor density in the CPu and 
NAc (CPu: housing conditions: F1-12=0.01988; p=0.8887; drug treatment: F1-12=1.858; 
p=0.1813; NAc: housing conditions: F1-12=0.1370; p=0.7140; drug treatment: F1-12=0.2175; 
p=0.6446). 
Effect of AM251 administration on glutamate NMDA receptor density 
Figure 18b represents the effect of AM251 (or vehicle) treatment on NMDA receptor 
density in respect to the different housing conditions. 
A significant down-regulation of NMDA receptor density was evident in isolated rats in the 
CPu (F1-12=9.408; p=0.0050). Moreover, isolation rearing induced a significant up-
regulation of the receptor in the NAc (F1-12=23.32; p<0.0001). No changes were instead 
observed in the PFC (F1-12=0.8202; p=0.3734), Hippo (F1-12=3.485; p=0.0728), Amy (F1-
12=0.8727; p=0.3599) and Thal (F1-12=0.4155; p=0.5248) following isolation rearing. 
AM251 treatment did not affect [3H]MK-801 binding in group-reared controls in any of the 
brain areas analyzed but completely recovered isolation rearing-induced alterations in the 
CPu (drug: F1-12=6.718; p=0.01550; housing conditions x drug interaction: F1-12=4.404; 
p=0.0457) and NAc (drug: F1-12=6.254; p=0.0190; housing conditions x drug interaction: F1-
12=14.01; p=0.0009). Moreover, in the Hippo two-way ANOVA revealed a significant 
housing conditions x drug treatment interaction (F1-12=20.38; p=0.0001), NMDA receptor 
binding being significantly down-regulated in isolated rats following AM251 treatment. 
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Overview 
The overarching goal of this collective body of research was to examine whether 
alterations of the endocannabinoid signaling, either induced by exogenous administration 
of THC during adolescence or by a neurodevelopment procedure such as the social 
isolation rearing from weaning, could be associated with the development of psychotic-like 
symptoms in rats and to determine the efficacy of a modulation of the endocannabinoid 
system, through AM251, in reverting schizophrenia-like signs and in restoring 
endocannabinoid system functionality. 
The research described in Study n. 1 argues that prolonged exposure to THC during 
adolescence represents a risk factor for the development of a complex schizoaffective-like 
phenotype later in life. This behavioral picture is associated with marked alterations in the 
GABAergic system within the PFC. The observed alterations of GABA transmission may 
be directly related to the altered behavior in the FST observed in adult THC-treated rats, 
as silencing GAD67 in the PFC results in increased time spent in immobility in the test. In 
contrast, they do not appear to be related to the other behavioral alterations triggered by 
adolescent THC treatment. Instead, the psychotic-like component of THC-induced 
behavioral phenotype (i.e. sensitization to acute PCP) may be ascribed to increased 
neuronal activation as well as enhanced glutamate levels within the PFC and CPu. 
In Study n. 2, it was demonstrated that alterations of the endocannabinoid system, in 
terms of CB1 receptor functionality and endocannabinoid content, were present in a 
neurodevelopmental animal model of schizophrenia based on the post-weaning social 
isolation procedure. Moreover, in these animals we also found significant alterations in 
dopamine D1 and D2 as well as glutamate NMDA receptor densities. More interestingly, 
the pharmacological modulation of the endocannabinoid system through AM251 was 
effective in counteracting the schizophrenia-like phenotype observed in isolation-reared 
rats and this recovery at behavioral level was paralleled by the rescue of CB1 receptor 
functionality as well as the normalization of endocannabinoid contents within specific brain 
regions. Moreover, AM251 administration also partially counteracted the isolation-induced 
changes in dopamine and glutamate receptors, possibly contributing to the observed 
recovery at behavioral level. 
A detailed discussion of the studies presented in this thesis is provided in the following 
sections. 
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Adolescent delta-9-tetrahydrocannabinol (THC) exposure as a risk factor for 
developing schizophrenia later in life 
Behavioral results 
The results here presented provide evidence that adolescent THC treatment leads to long-
term behavioral alterations in adult female rats characterized by the presence of 
recognition memory deficits, social withdrawal and altered emotional reactivity, closely 
resembling the ones induced by sub-chronic PCP administration. 
These findings confirm and expand our previous studies demonstrating the presence of a 
complex depressive-like phenotype in adult female rats that underwent adolescent THC 
exposure, characterized by the presence of anhedonia, behavioral despair in the FST and 
reduced sociability as well as significant deficits in spatial working memory and object 
recognition memory (Realini et al, 2011; Rubino et al, 2008, 2009). 
Furthermore, here we demonstrated for the first time that, besides the cognitive 
impairments and altered emotional reactivity, adolescent THC administration also induces 
a sensitization to the locomotor activating effect of acute PCP when administered in 
adulthood. In fact, adult animals exposed to THC during adolescence showed an 
exacerbated behavioral response to acute PCP compared with vehicle-treated controls, in 
terms of both locomotor activation and stereotyped behaviors. This effect is consistent with 
the presence of a psychotic-like phenotype, since sensitization to PCP-induced 
hyperactivity is widely recognized as an index with translational relevance to the positive 
symptoms of schizophrenia. To our knowledge, this is the first time that the long-lasting 
consequences of adolescent cannabinoid exposure on psychoactive drug-induced 
locomotor activation were assessed. 
Thus, the present data extend our earlier findings and indicate that the behavioral picture 
triggered by adolescent THC treatment is more complex than what previously thought. In 
fact, the simultaneous presence of pronounced depressive-like behaviors, cognitive 
deficits as well as psychotic-like signs suggests that adolescent THC exposure had led to 
a behavioral phenotype that cannot be defined as depressive-like behaviors, but rather be 
ascribed to a more complex schizoaffective-like disorder. 
As a whole, our data support the hypothesis that adolescent exposure to THC might 
represent a risk factor for developing psychotic-like symptoms in adulthood. 
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Biochemical results 
Alterations in several markers of the inhibitory neurotransmission have been demonstrated 
in multiple cortical regions of schizophrenic patients (Curley and Lewis, 2012) as well as in 
different animal models of the pathology (Powell et al, 2012). 
Here, we demonstrated that the psychotic-like phenotype observed in adult rats that 
underwent adolescent THC treatment is associated with marked alterations in the 
GABAergic system within the PFC. Specifically, adolescent THC exposure resulted in 
lower levels of GAD67, the enzyme responsible for most GABA synthesis, and, 
accordingly, PFC basal GABA levels were reduced in adult THC-treated rats compared 
with vehicle-treated animals. In contrast, adolescent THC exposure did not affect PV, 
VGAT and CCK expression. 
These data suggest that THC exposure during adolescence disturbs the physiological 
maturation of the GABA system within the PFC, possibly delaying the physiological 
increase in GAD67 that occurs during adolescence.  
In line with this, in studies examining brain tissue from schizophrenic patients, concomitant 
reductions of GAD67 and CB1 receptor mRNA levels within cortical regions have been 
observed (Akbarian and Huang, 2006; Eggan et al, 2008). Accordingly, in the present 
study we found that adolescent THC exposure resulted in long-term alterations of GAD67 
levels in the PFC, whereas no changes were observed in the hippocampus. Interestingly, 
a reduction in CB1 receptor was also observed within this brain region following 
adolescent THC exposure (Rubino et al., personal communication). 
Cortical GAD67 expression has been found to be reduced in PV-positive interneurons in 
both schizophrenic brains (Hashimoto et al, 2003) and animal models of schizophrenia 
(Wang et al, 2008). Here, we demonstrated that GAD67 levels were reduced in cortical 
PV-containing interneurons following adolescent THC exposure. However, we also 
reported, for the first time, that adolescent THC treatment also resulted in reduced GAD67 
immunoreactivity in CCK-containing interneurons, possibly suggesting that also alterations 
in this neuronal GABAergic subpopulation might play a role in THC-induced 
schizoaffective-like disorder. 
Within the neocortex, CB1 receptor is expressed at high levels in a subpopulation of CCK-
positive basket interneurons whereas it is not expressed in PV-positive interneurons 
(Marsicano and Lutz, 1999). It has been recently demonstrated that agonism at CB1 
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receptor affects GABAergic transmission in the PFC. Indeed, reduced gamma oscillations 
have been reported in the PFC following administration of the synthetic cannabinoid 
agonist, CP-55,940 (Kucewicz et al, 2011). Interestingly, at cellular level, the decrease in 
gamma oscillations has been linked to reduced function of PV-positive interneurons 
(Volman et al, 2011), which lack CB1 receptor. Since CCK-positive and PV-positive cells 
have been demonstrated to be anatomically and functionally coupled (Armstrong and 
Soltesz, 2012), we can suggest that, following adolescent THC administration, primary 
alterations in CCK-containing interneurons might have occurred triggering, in turn, the 
alterations observed in PV-positive cells. 
As a whole, lower GAD67 expression appears to be a critical hallmark of schizophrenia, 
but it is still unknown if and to what extent deficits in GAD67 contribute to the pathogenesis 
of the disease. In this study, we demonstrated that the deficit in GAD67 was not present 
24 hours (PND 46) nor 15 days (PND 60) after discontinuing THC administration but only 
developed in adulthood (PND 75), suggesting a strong positive correlation among the 
deficit in GAD67 and the behavioral impairments observed in adult THC-treated rats. 
To investigate whether reduced GAD67 expression is sufficient in determining the 
behavioral alterations observed in adult rats that underwent adolescent THC exposure, we 
silenced GAD67 expression selectively in the PFC of adult naïve rats and tested them for 
behavior. Silencing GAD67 expression in the PFC was sufficient to impact rats’ behavior in 
the FST: indeed, we observed an 80% increase in the time spent in immobility compared 
with controls, an effect that was paralleled by reductions in climbing and swimming 
activities. In contrast, reduced GAD67 expression did not affect animal behaviors in the 
NOR and SI tests and did not alter the response to acute PCP.  
The present results suggest that lower GAD67 levels may be directly related to the 
behavioral despair observed in adult THC-treated rats whereas THC-induced cognitive 
deficits and social withdrawal may rely on other molecular mechanisms, different from the 
ones considered in the present study, or may be dependent upon concomitant alterations 
that involve multiple neurotransmitter systems. 
Moreover, here we demonstrated that an altered neuronal activation may underlie the 
behavioral sensitization to acute PCP observed in adult THC-treated rats. 
Using c-Fos as a functional anatomical marker of activated neurons within the central 
nervous system (Kovacs, 2008), we reported that c-Fos immunoreactivity was significantly 
enhanced in the PFC and CPu of adult THC-exposed animals in response to acute PCP. 
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This increase in neuronal activation may be dependent upon enhanced extracellular 
glutamate levels following acute PCP injection (Adams and Moghaddam, 1998). 
Accordingly, acute PCP administration resulted in enhanced PFC and CPu glutamate 
levels in THC-treated rats, but not in vehicle-treated animals. 
As a whole, these findings support the hypothesis that prolonged exposure to THC during 
adolescence represents a risk factor for the development of a complex schizoaffective-like 
phenotype later in life. This behavioral picture is associated with marked alterations in the 
GABAergic system within the PFC. Indeed, adolescent THC exposure results in reduced 
GABA synthesis and levels in the PFC. Reduced cortical GAD67 expression may be 
directly related to the altered behavior in the FST observed in adult THC-treated rats, as 
silencing GAD67 in the PFC results in increased time spent in immobility in the test, but 
does not appear to be related to the psychotic-like component of the THC-induced 
behavioral phenotype, as delivery of GAD67 siRNA in the PFC did not affect the 
behavioral response induced by acute PCP administration. In contrast, the sensitization to 
acute PCP reported in adult THC-treated rats may be ascribed to increased neuronal 
activation as well as enhanced glutamate levels within the PFC and CPu. 
Modulation of the endocannabinoid system in a neurodevelpmental model of 
schizophrenia 
Behavioral and biochemical characterization of the isolation induced phenotype  
Rearing rats in isolation from weaning results in long-term abnormalities on brain structure, 
neurotransmitter function and behavior compared to group housed controls (Lapiz et al., 
2003). In our hands, after five weeks of isolation rearing, rats presented a marked increase 
in total horizontal locomotor activity, in isolation reared rats compared to group housed 
controls without any differences in total vertical activity between the two groups. Moreover, 
rats reared in isolation showed a cognitive impairment in the novel object recognition test 
and a significant increase in the number of aggressive behaviors. compared to socially-
reared controls. Consistent with the presence of a schizophrenia-like phenotype, we 
demonstrated here the presence of a robust deficits in PPI response in isolated rats 
compared to socially reared littermates thus reinforcing the original findings that this 
environmental manipulation provides a viable, non-pharmacological model of impaired 
PPI. 
Several lines of evidence suggest that dysregulation of endocannabinoid signaling might 
be specifically implicated in the behavioral phenotype exhibited by isolated animals 
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(Malone et al., 2008; Robinson et al., 2010). Thus, in these animals, using 
autoradiographic techniques, we explored CB1 receptor levels in isolation reared rats and 
group housed controls but found no changes in CB1 receptor binding sites in all the brain 
regions considered. These data appear in contrast with the results reported in recent 
papers that demonstrated a reduction in CB1 immunoreactivity restricted to caudate 
putamen and amygdala (Malone et al., 2008) or, more recently, an increase of the CB1 
receptor mRNA expression (Robinson et al., 2010). The discrepancies between our study 
and the ones of Malone and Robinson can be due to the different techniques used to 
evaluate CB1 receptor density (autoradiographic binding assay or immunohistochemistry), 
the different rat species (Lister Hooded or Sprague-Dawley) and the duration of isolation 
rearing protocol (5 weeks or 8 weeks), in fact it can be possible that a downregulation in 
CB1 receptor could appear after longer periods of isolation. 
Despite the results concerning the CB1 receptor density, our data show a widely diffused 
alterations in the CB1 receptor/G protein coupling in isolated reared rats. In particular, it 
was significantly reduced in the prefrontal cortex (pf ctx) (-35%), caudate putamen (CPu) (-
45%), nucleus accumbens (NAc) (-52%), hippocampus (Hippo) (-39%) and in the ventral 
tegmental area (VTA) (-58%). 
The presence of a widespread desensitization of CB1 receptors in specific brain regions of 
isolated rats suggests the possibility of an enhanced endocannabinoid tone in isolation 
reared rats. Accordingly, significant differences in the endocannabinoid content were 
evident in isolated rats compared to group housed controls in all the brain regions 
analyzed. The most intriguing finding was that these alterations mainly involved the 
endocannabinoid 2-AG, the levels of which were differentially regulated in isolated rats 
depending on the brain area considered. Particularly, 2-AG levels were significantly higher 
in the CPu and Hippo, whereas significant decreases were present in the PFC and NAc 
following 5 weeks of isolation rearing. No changes in the other endocannabinoid, AEA, or 
in the AEA-related mediators, OEA and PEA, occurred in any of the brain regions under 
investigation, except for a significant increase in PEA levels in the PFC. 
Previous studies demonstrated that environmental stressors alter the expression of 
enzymes involved in 2-AG biosynthesis and degradation in brain regions controlling 
emotion and motor behavior (Suarez et al., 2010; Sutt et al., 2008). Moreover, the 
presence of alterations in 2-AG content following isolation rearing procedure is further 
supported by the recent findings of Robinson et al. (2010), demonstrating the presence of 
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widespread alterations in DAGLα and DAGLβ mRNA as well as MAGL mRNA in isolation 
reared rats. In line with these data we speculate that the alteration in 2-AG tissue 
concentrations reported here might be due to alteration in the enzymes involved in  2-AG 
synthesis or degradation. To date only the work of Sciolino et al. (2010) directly 
investigated the presence of alterations in the endocannabinoid levels in isolated rats. In 
this study, increases in 2-AG levels were present in the PFC while no changes were found 
in the NAc and Hippo. This discrepancy with our present findings could be ascribed to the 
different isolation rearing protocol as well as to the different rat strain used, since strain 
differences in the isolation-induced alterations have already been reported for other 
behavioral parameters (Weiss et al., 2000). 
As a whole, these data clearly indicate that post-weaning social isolation procedures in 
rats induce marked alterations in specific component of the endocannabinoid system, 
suggesting that abnormal endocannabinoid signaling could represent one of the molecular 
underpinnings of isolation-induced behavioral deficits. Inasmuch as the endocannabinoid 
system plays a homeostatic role during brain development, it is tempting to speculate that 
disrupted endocannabinoid signaling could negatively affect the maturation of other 
neurotransmitter systems within the central nervous system, leading to abnormal 
neurotransmission. For this reason, we investigated here also the possible impact of 
altered endocannabinoid neuromodulatory function on the interface between glutamatergic 
and dopaminergic function by assessing dopamine D1 and D2 as well as NMDA receptor 
densities in isolated and group housed rats. 
Interestingly, a significant reduction in D1 receptor and a significant increase in D2 
receptor density were observed in the PFC of isolated rats compared to group reared 
controls. An imbalance between D1 and D2 receptors has been suggested to contribute to 
the symptoms of schizophrenia (Scott and Aperia, 2009). In agreement with our present 
findings, a PET study showed that schizophrenic patients have reduced dopamine D1 
receptor binding in the PFC, which is related to the severity of the negative symptoms 
(Okubo et al., 1997; Sedvall and Farde, 1996), and, recently, a reduction of D1 receptor 
density was reported in the PFC of isolated rats (Toua et al., 2010  Moreover, the increase 
in D2 receptors we observed in the PFC of isolated animals agrees with first PET studies 
suggesting that dopamine D2 receptors are indeed up-regulated in schizophrenia patients 
(Wong et al., 1986). Based on the suggestion of a strong interaction between D1 and D2 
second messenger systems (Seeman et al., 1989; Strange, 1991), it could be suggested 
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that the opposite effect of isolation rearing on D1 and D2 receptor densities might reflect a 
compensatory mechanism. Furthermore, both D1 and D2 receptors are involved in the 
regulation of PPI in rats (Geyer et al., 2001), with most of the evidence indicating a major 
contribution of D2 rather than D1 receptors to this behavior. However, a role of D1 
receptors in the modulation of PPI has been also highlighted (Ralph-Williams et al., 2003), 
and thus it is more likely that D1 and D2 receptors work together to modulate PPI in rats. 
As a whole, these data suggest the presence of altered dopamine transmission in the PFC 
following isolation rearing procedure. 
Intriguingly, changes in NMDA receptor density were also present in rats reared in 
isolation. Particularly, we found a significant reduction of NMDA receptor binding in the 
CPu paralleled by a significant increase in the NAc. Functional interactions involving 
dopamine and NMDA receptors have been documented in several forebrain regions and 
associated with the modulation of locomotor activity and memory processes (Adriani et al., 
1998; Tseng and O’Donnell, 2003). Moreover, interactions at the dopamine-glutamate 
interface have been implicated in the regulation of sensorimotor gating (Wan and 
Swerdlow, 1996). Therefore, altered dopamine and glutamate transmission in the forebrain 
regions might underlie the disrupted behavior we observed in isolated rats. 
Although a causal link cannot be established based uniquely on our present data, it is 
tempting to hypothesize that aberrant endocannabinoid signaling, such as that observed 
here in isolation reared rats, could negatively impact on normal behavior and 
neurotransmission in these animals and contribute, through this mechanism, to the 
behavioral alterations that accompany this condition. In this scenario, pharmacological 
interventions aimed at restoring normal endocannabinoid transmission could be effective 
in recovering isolation-induced schizophrenia-like phenotype as well as the related 
neurochemical alterations. 
Effect of AM251 treatment on isolation-induced schizophrenia-like phenotype 
Recent findings suggest that CB1 receptor antagonists possess a pharmacological profile 
reminiscent of atypical antipsychotics (Guidali et al., 2010). In the present work, acute 
AM251 administration did not reverse isolation-induced cognitive impairment and social 
withdrawal, suggesting that a single AM251 administration may not be sufficient to reach a 
beneficial effect on isolation rearing-induced behavioral deficits. The results obtained with 
chronic AM251 treatment appear more interesting. To the best of our knowledge, this is 
the first study evaluating the effect of a chronic manipulation of the endocannabinoid 
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system in isolation reared rats. Rats were chronically administered with AM251 (or vehicle) 
daily for 3 weeks as previously reported for the atypical antipsychotic clozapine (Li et al., 
2007b). It is worth to note that the behavioral alterations observed in rats reared in 
isolation  are particularly influenced by chronic handling (Sciolino et al., 2010) and this 
might be taken into consideration when performing a chronic pharmacological treatment in 
socially-isolated rats. In our model, chronic handling did not affect the cognitive impairment 
induced by isolation whereas the aggressive behaviors were reduced by handling but 
remained still significantly elevated when compared to group housed controls. 
Intriguingly, chronic AM251 alone did not affect the cognitive functions in group housed 
controls. However, chronic treatment of AM251 to isolation reared rats, significantly 
improved the performance in the novel object recognition test and reduced the aggressive 
behaviors in the social interaction test. It is worth to note that this recovery due to chronic 
AM251 administration on isolation rearing-induced cognitive impairment and aggressive 
behaviors persisted till 10 days after discontinuing the treatment, indicating a long lasting 
effect of the cannabinoid antagonist on psychotic-like symptoms. This is an intriguing 
property of AM251 since, following treatment with antipsychotic drugs, it has been 
demonstrated a relapse of psychotic symptoms when taken off the drug (Li et al., 2007a) 
and, moreover, antipsychotics are have been associated with untoward effects upon 
withdrawal (Lee and Robertson, 1997). 
Intriguingly, AM251 also completely counteracted PPI deficits in isolation reared rats. 
Since both typical or atypical antipsychotic treatments are effective in normalizing PPI 
responses in schizophrenic patients as well as in isolated rats (Kumari and Sharma, 2002; 
Powell and Geyer, 2002), the beneficial effect of AM251 is consistent with a potential 
antipsychotic-like profile of this compound. However, the mechanisms underlying this 
antipsychotic effect of AM251 are still unclear 
Effect of AM251 treatment on isolation-induced alterations of the endocannabinoid system, 
and dopamine/glutamate receptor densities 
Here we demonstrated that psychotic symptoms in isolation reared rats are accompanied 
by alterations in the endocannabinoid system, thus we first investigated a direct effect of 
AM251 treatment on CB1 receptor functionality and endocannabinoid content. 
Chronic AM251 had no effects on CB1 receptor density both in grouped and isolated rats. 
The alterations in CB1 receptor/G protein coupling reported in isolated rats in the pf ctx, 
NAc, hHippo and VTA were still evident after 3 weeks of chronic vehicle chronic treatment, 
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except for the reduction in the CPu that seemed to have been counteracted by chronic 
handling. Interestingly, chronic AM251 completely restored CB1 receptor functionality in 
the pf ctx, NAc, hHippo and VTA in isolated rats without having per se any effect in all the 
brain areas analyzed. 
As far as endocannabinoid levels is concerned, there are some isolation-induced changes 
in endocannabinoids that seem to be transient and can be therefore reversed by even a 
mild environmental manipulation, such as, as shown here, daily handling. In fact, a 
handling effect was clearly evident in the CPu of isolated rats, where chronic handling 
completely counteracted the isolation-induced increase in 2-AG content. Since in this 
same brain area, handling counteracted also the isolation-induced desensitization of CB1 
receptors, this latter effect might be ascribed to the normalization of 2-AG levels in this 
brain area. Consistent with a role of the CPu in the development of aggressiveness, the 
above mentioned handling effects might also have contributed to the partial recovery of 
aggressive behaviors observed in isolated rats following vehicle administration. 
On the other hand, some of the other isolation-induced changes observed here were less 
sensitive to chronic handling and might therefore play a more relevant role in the 
development of the psychotic-like phenotype. Indeed, the reductions in 2-AG levels in the 
PFC and NAc, as well as the increase of 2-AG in the Hippo, were still evident in isolated 
rats undergoing 3 weeks of vehicle treatment. More importantly, these persistent 
alterations in 2-AG contents were completely counteracted by chronic AM251 
administration in all the corresponding brain regions. Therefore, given the observation that 
AM251 concomitantly reversed also the behavioral and schizophrenia-like consequences 
of isolation, it seems reasonable to suggest that these specific long-lasting changes in 
endocannabinoid signaling may account for the behavioral recovery observed in isolation 
reared rats, although further studies are needed to clarify the underlying mechanisms. 
Intriguingly, AM251 administration also partially counteracted the isolation-induced 
changes in dopamine and glutamate receptors, possibly through the rescue of normal 
endocannabinoid system functionality. It is possible that only persistent alterations in 
endocannabinoid levels induced by isolation can affect to some extent dopamine and 
glutamate receptor expression. However, AM251 restored D2 receptor binding in the PFC 
of isolated rats but failed to normalize D1 receptor density in the same brain area. While 
much attention has been focused on striatal D2 receptors in schizophrenia, recent 
evidence has implicated cortical D2 receptors as the important sites of action of 
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antipsychotic drugs and changes in the dopamine receptors in the cerebral cortex need to 
be taken into account when evaluating the regulatory actions of neuroleptics (Lidow et al., 
1998). Therefore, the observed recovery at D2 receptor in the PFC following AM251 
treatment could be one of the molecular underpinnings of the antipsychotic-like profile of 
this compound. Furthermore, a role for the glutamatergic system in the behavioral 
recovery due to AM251 administration could not be ruled out, since AM251 treatment 
completely rescued NMDA receptor binding in the CPu and NAc of isolated animals. In 
conclusion, the present results demonstrate that chronic AM251 administration is effective 
in reversing schizophrenia-like signs in isolation reared rats, thus providing further 
evidence of an antipsychotic potential for antagonism at CB1 receptors. Imbalances in the 
endocannabinoid system, specifically CB1 receptor and 2-AG levels, could represent one 
of the molecular abnormalities related to the disrupted behavior observed in isolated rats 
and their normalization may account for AM251-induced recovery of psychotic-like 
symptoms in this animal model. Furthermore, the present findings indicate the occurrence, 
following isolation rearing procedure, of dopamine and glutamate disturbances in brain 
regions relevant to schizophrenia-like behaviors. The ability of AM251 to partially 
normalize these disturbances may also participate in its antipsychotic action. 
  
 
 
 
 
 
 
 
CONCLUSIONS 
Conclusions 
60 
 
A unifying theory of endocannabinoid  system and schizophrenia 
The body of research described in this thesis has highlighted that maladaptations of the 
endocannabinoid system either induced by a direct manipulation of the system (through 
adolescent THC exposure, or triggered by a neurodevelopmental insult (such as post-
weaning social isolation) are associated with the development of psychotic-like symptoms 
in rats. 
We speculate that exogenous cannabinoids or other insults during sensitive periods of 
brain development, such as adolescence, may disrupt the neuromodulatory role exerted 
by the endocannabinoid system on neurotransmission (particularly GABA) ultimately 
resulting in a major vulnerability to develop psychiatric disorders. Accordingly, in the 
present thesis the psychotic-like phenotype present in adult animals that underwent 
adolescent THC exposure was associated with marked changes in the GABAergic system 
within the PFC. 
If cannabinoid dysregulation is considered as one of the potential causes of schizophrenia 
symptomology or a setting event for the disorder, then it may be possible to design 
therapeutic interventions to address this issue by using the wide range of ligands that 
directly or indirectly act on CB1 receptors and on the enzymes that synthesize or inactivate 
the endocannabinoids. 
In line with this, we here demonstrated that CB1 receptor blockade through chronic AM251 
treatment is effective in recovering the schizophrenia-like symptoms associated with post-
weaning social isolation in rats. 
Intriguingly, rimonabant, a CB1 receptor antagonist/inverse agonist, was tested with 
promising results in a sixteen-week, double-blind, placebo-controlled study in people with 
schizophrenia or schizoaffective disorder before being removed from the market because 
of its severe adverse effects (Kelly et al. 2011). However, a major limitation of this study is 
the small sample size, due to its premature termination (rimonabant marketing was 
suspended in 2008), and consequent limited power to detect efficacy or rare adverse 
events. Thus, additional controlled trials are required to confirm the possible therapeutic 
exploitation and determine the safety of cannabinoid compounds. More consistent findings 
have been obtained using the non-psychoactive cannabinoid, cannabidiol. In fact, its 
administration was effective in reverting the positive and negative symptoms of 
schizophrenia both in animal studies and clinical trials and its antipsychotic action may be 
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ascribed to its ability to increase serum levels of AEA by inhibiting the enzymatic 
degradation of this endocannabinoid (Leweke et al. 2012). 
Of course, additional controlled trials are still required to confirm the possible therapeutic 
exploitation and determine the safety of cannabinoid compounds. 
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Figure 1 
 
 
 
Figure 1: Adolescent THC treatment schedule (A) and sub-chronic PCP protocol (B). (C) Protocol of acute PCP injection in adult rats 
that underwent adolescent THC administration.
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Figure 2 
 
Figure 2: Comparison between the behavioral alterations induced by adolescent THC exposure and sub-chronic PCP treatment in 
adult rats in the NOR test (A), social interaction test (B) and FST (C). Data are expressed as mean ± S.E.M. of six animals per group. 
***p<0.001; **p<0.01; *p<0.05 vs vehicle (Bonferroni’s post hoc test). (D) Locomotor activity and stereotyped behaviors in 
response to acute PCP administration in THC-treated rats. Data are expressed as mean ± S.E.M. of six animals per group. 
***p<0.001; *p<0.05 vs vehicle-saline; °°°p<0.001; °p<0.05 vs vehicle-PCP; ^^^p<0.001; ^p<0.05 vs THC-saline (Bonferroni’s post 
hoc test).
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Figure 3  
 
Figure 3: (A) GAD67, parvalbumin (PV), VGAT and cholecystokinin (CCK) levels in the PFC of adult animals exposed to THC during 
adolescence. Data are expressed as mean ± S.E.M. of four animals per group. **p<0.01 vs vehicle (unpaired Student’s t test). (B) 
Characterization of the kinetics of GAD67 levels from mid adolescence to adulthood in the PFC of THC-exposed animals. Data are 
expressed as mean ± S.E.M. of four animals per group at each time point. ***p<0.001 vs vehicle at PND 75; °°°p<0.001 vs PND 46 
(unpaired Student’s t test). (C) Effects of adolescent THC exposure on basal extracellular GABA levels in the prefrontal cortex of the 
awake rat. Each value represents the mean ± S.E.M. (n=8). Statistical analysis was performed using Student's t-test; *P<0.05 
significantly different from the vehicle-treated group.
Figures 
65 
 
Figure 4  
 
Figure 4: Representative dual-label immunofluorescence images for GAD67 and PV (A) and for GAD67 and CCK (B) in the PFC of 
THC-exposed animals. Quantification was determined as the percentage of GAD67 and PV or CCK double positive cells among the 
total number of PV or CCK positive cells. Data are expressed as mean ± S.E.M. of four animals per group. ***p<0.001; *p<0.05 vs 
vehicle (unpaired Student’s t test).
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Figure 5  
 
Figure 5: (A) GAD67 immunoreactivity in the PFC 72 hours after bilateral injection of GAD67 siRNA. Behavioral responses in the 
NOR test (B), social interaction test (C), FST (D) and effect of acute PCP administration (2.5 mg/kg) (E) 72 hours after bilateral 
injection of GAD67 siRNA. Data are expressed as mean ± S.E.M. of five animals per group. ***p<0.001; **p<0.01; *p<0.05 vs non-
operated animals; °°°p<0.001; °°p<0.01; °p<0.05 vs sham-operated animals; ###p<0.001; ##p<0.01; #p<0.05 vs scramble siRNA 
(Bonferroni’s post hoc test).
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Figure 6 
 
Figure 6: (A) c-Fos immunoreactivity in response to acute PCP administration in THC-treated rats in the Prefrontal Cortex (PFC) and 
Caudate Putamen (CPu). Data are expressed as mean ± S.E.M. of four animals per group. ***p<0.001; *p<0.05 vs vehicle-saline; 
°°°p<0.001; °p<0.05 vs vehicle-PCP; ^^^p<0.001; ^^p<0.01; ^p<0.05 vs THC-saline (Bonferroni’s post hoc test). (B and C): Effects of 
an acute phencyclidine (PCP) injection (2.5 mg/kg, i.p.) on prefrontal cortex (B) and dorsal striatum (C) extracellular glutamate (left 
panel) and GABA (right panel) levels in rats treated during adolescence with vehicle or THC. The vertical arrows indicate the time of 
the injection of PCP. The results are expressed as percentage of the mean of the three basal values before PCP injection. Each point 
represents the mean ± S.E.M. of six animals. Left panel: *P<0.05, ** P<0.01 significantly different from vehicle groups; °P<0.05 
significantly different from vehicle – PCP group according to ANOVA followed by the Newman-Keuls test for multiple comparisons. 
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Figure 7 
 
 
 
 
 
 
 
Figure 7: Treatment schedule 
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Figure 8 
 
Figure 8: Behavioral phenotype after 5 weeks of isolation rearing. A: Horizontal (left) and vertical (right) activity assessed in the 
activity cage. B: Exploration time of the familiar versus novel object and the discrimination index during the test phase in the novel 
object recognition (NOR) test. C: number of aggressive behaviors (left) and time spent in social behaviors (right) during the social 
interaction test. Results are expressed as mean± S.E.M. of six animals per group. D: Percent prepulse inhibition (%PPI) after 5 weeks 
of isolation rearing. Data are expressed as the average PPI response of 10 animals per group over the 3 prepulse intensities. 
***p<0.001; *p<0.05 vs grouped at the respective dB intensity (Unpaired Student’s t-test) 
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Figure 9 
 
 
 
 
Figure 9: Effect of 5 weeks of isolation rearing on CB1 receptor density and functionality. A: [
3
H]CP-55,940 receptor 
autoradiographic binding. B: CP-55,940-stimulated [
35
S]GTPγS binding in autoradiography. Prefrontal cortex (pf ctx), nucleus 
accumbens (NAc), caudate putamen (CPu), globus pallidus (GP), hypothalamus (hypo), thalamus (thal), hippocampus (hippo), 
amygdale (amy), substantia nigra (SN), periaqueductal grey (PAG), ventral tegmental area (VTA), cerebellum (cer). Results are 
expressed as mean± S.E.M. of four animals per group. *p<0.05, **p<0.01 vs GROUPED (unpaired Student’s t-test) 
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Figure 10 
 
 
 
 
 
Figure 10: Brain tissue concentrations of endocannabinoids (AEA, 2-AG) and AEA-like mediators (PEA, OEA) after 5 weeks of 
isolation rearing. Brain areas: Prefrontal cortex (PFC); Caudate putamen (CPu); Nucleus accumbens (NAc); Hippocampus (Hippo). 
Data are expressed as the mean ± S.E.M. of four animals per group. *p<0.05 vs grouped (Unpaired Student’s t-test). 
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Figure 11 
 
 
 
 
 
Figure 11: Effect of 5 weeks of isolation rearing on (A) D1 and D2 receptor density and (B) NMDA receptor density. D1 and D2 
receptor densities were assessed through [
3
H]SCH23390 and [
3
H]Raclopride receptor binding, respectively. NMDA receptor density 
was assessed through [
3
H]MK801 receptor binding. Results are expressed as fmol/mg of tissue. Brain areas: Prefrontal cortex (PFC); 
Caudate putamen (CPu); Nucleus accumbens (NAc); Hippocampus (Hippo); Amygdala (Amy); Thalamus (Thal). Data are expressed 
as mean ± SEM of four animals per group. ***p<0.001; *p<0.05 vs grouped (Unpaired Student’s t-test). 
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Figure 12 
 
 
 
 
 
Figure 12: A: Effect of acute AM251 treatment (0.5 mg/kg) on isolation-induced cognitive deficit in the novel object recognition 
(NOR) test. The test was performed 80 minutes after AM251 administration. Represents the exploration time of the familiar versus 
novel object and the discrimination index during the test phase. B: Effect of acute AM251 treatment (0.5 mg/kg) in the social 
interaction test. The test was performed 80 minutes after AM251 administration. (Left) Represents the number of aggressive 
behaviors during the test session. (Right) Represents the time spent in active social behaviors. Data are expressed as mean± S.E.M. 
of five animals per group. **p<0.01, ***p<0.001 vs familiar object (unpaired Student’s t-test); ***p<0.001 vs grouped+vehicle 
(Bonferroni’s post-hoc test). 
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Figure 13 
 
 
Figure 13: Effect of chronic AM251 treatment (0.5 mg/kg) on isolation-induced cognitive deficit in the novel object recognition 
(NOR) performed 24 hours, 72 hours and 10 days after the last AM251 administration. Represents the exploration time of the 
familiar versus novel object and the discrimination index during the test phase. Data are expressed as mean± S.E.M. of five animals 
per group. **p<0.01, ***p<0.001 vs familiar object (unpaired Student’s t-test); **p<0.01,*p<0.05 vs grouped+vehicle; °°p<0.01 vs 
isolated+vehicle (Bonferroni’s post-hoc test). 
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Figure 14 
 
 
 
Figure 14: Effect of chronic AM251 treatment (0.5 mg/kg) during the social interaction test performed 24 hours, 72 hours and 10 
days after the last AM251 administration. (Left): Number of aggressive events (Right) Time spent in active social behavior during 
the test session. Results are expressed as mean± S.E.M. of five animals per group. **p<0.01,***p<0.001 vs grouped+vehicle 
°°p<0.01,°°°p<0.01 vs isolated+vehicle (Bonferroni’s post-hoc test). 
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Figure 15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Percent prepulse inhibition (%PPI) after chronic AM251 (or vehicle) treatment in isolated and group housed rats. Data 
are expressed as the average PPI response of five animals per group over the 3 prepulse intensities. **p<0.01; *p<0.05 vs grouped 
at the respective dB intensity (Bonferroni’s post-hoc test). 
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Figure 16 
 
 
 
 
 
Figure 16: Effect of chronic AM251 on CB1 receptor density and functionality. A: [
3
H]CP-55,940 receptor autoradiographic binding. 
B: CP-55,940-stimulated [
35
S]GTPγS binding in autoradiography. Results are expressed as mean± S.E.M. of four animals per group. 
*p<0.05, **p<0.01 vs GROUPED+vehicle; °°p<0.01, °°°p<0.001 vs ISOLATED+vehicle (Bonferroni’s post-hoc test) 
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Figure 17 
 
 
 
 
 
Figure 17: Brain tissue concentrations of endocannabinoids (AEA, 2-AG) and AEA-like mediators (PEA, OEA) after chronic AM251 or 
vehicle treatment in isolated and group housed rats. Brain areas: Prefrontal cortex (PFC); Nucleus accumbens (NAc); Caudate 
putamen (CPu); Hippocampus (Hippo). Data are expressed as the mean ± S.E.M. of four animals per group. *p<0.05 vs grouped 
(Bonferroni’s post-hoc test). 
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Figure 18 
 
 
 
 
 
Figure 18: Effect of chronic AM251 (or vehicle) treatment on (A) D1 and D2 receptor density and (B) NMDA receptor density. D1 
and D2 receptor densities were assessed through [
3
H]SCH23390 and [
3
H]Raclopride receptor binding, respectively. NMDA receptor 
density was assessed through [
3
H]MK801 receptor binding. Results are expressed as fmol/mg of tissue. Brain areas: Prefrontal 
cortex (PFC); Caudate putamen (CPu); Nucleus accumbens (NAc); Hippocampus (Hippo); Amygdala (Amy); Thalamus (Thal). Data are 
expressed as mean ± SEM of four animals per group. ***p<0.001; **p<0.01; *p<0.05 vs grouped (Bonferroni’s post-hoc test) 
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